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Abstract
HIV pre-exposure prophylaxis (PrEP) of which advocates the use of antiretroviral (ARV) agents
by uninfected individuals at high risk infection, has recently become a promising preventive
measure against sexual HIV transmission. While results from clinical trials undertaken in dif-
ferent parts of the world hold the promise that PrEP intervention could significantly stem the
risk of new sexual HIV transmission, very little attention has so far been given to the analysis
of the impact of PrEP strategy in mathematical modelling to explore the processes that inform
the current trends and other possible feedback mechanisms that can not be captured by the
clinical trials. In this research study, we develop mathematical HIV models to investigate the
impact of PrEP use as a single intervention and PrEP intervention in combination with other
strategies such as ARV therapy (ART) and post-infection educational support services, on HIV
incidence and prevalence. Thus, throughout the models analysis, PrEP awareness level, PrEP
efficacy level, and ARV treatment rate are considered as key aspects of HIV control. PrEP
drug resistance is also considered in our model analysis to examine its contribution to the HIV
infection spread. PrEP as a control strategy, is first considered as a single intervention to
examine different PrEP intervention scenarios where PrEP use and PrEP efficacy are imple-
mented at high/low levels. Results obtained suggest that the strategy with high PrEP use and
high PrEP efficacy level significantly reduces HIV incidence, compared to the other strategies
considered, but may not continuously keep the HIV burden under check. ART intervention is
thus incorporated into the PrEP model to assess the benefit of combining both strategies in
reducing new infections, compared with PrEP intervention alone. The results show that strate-
gies with PrEP and ART interventions offer the best benefits in new HIV infections reduction
when efficacy and adherence to PrEP and ART are maintained at high levels. The results also
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show that the contribution of PrEP drug resistance into the spread of HIV infection would
partially depend on the duration of inadvertent PrEP use by the already-infected individuals.
Results obtained from the PrEP intervention in combination with post-infection education for
risky behavioural change demonstrate that with time dependent controls (optimal controls),
the cumulative number of new HIV infections would be effectively reduced in a very short time.
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In the 1980s, when the Centers for Disease Control and Prevention (CDC) brought the world
attention to the Acquired Immunodeficiency Syndrome (AIDS) disease, which later was re-
vealed to be caused by the Human Immunodeficiency Virus (HIV), the scientific committee
and healthcare authorities optimistically believed that an effective vaccine or a cure would
soon be developed to effectively treat the reported ill patients so as to avoid an outbreak.
However, more than three decades later, neither a vaccine nor successful treatment proposed
could stop the transmission or effectively cure those carrying the virus. Alternative preven-
tive/treatment approaches have been developed and used to slow down the rapid progression
of HIV infection, but more than a million of people get infected and thousands die from the
disease every year. The global endemicity level of HIV infection remains alarming in every
part of the world, and there is a need to continuously conduct research and investigate of new
strategies that could systematically eradicate the HIV pandemic. Results from some recent
studies suggested new effective approaches, which were demonstrated potently effective in pre-
venting new HIV infections. The potent and the most promising approach, currently under
investigation, is the use of antiretroviral drugs by uninfected individuals at high risk, in the
form of pre-exposure prophylaxis (PrEP). In this study, mathematical HIV models are used
to investigate the impact of PrEP as a pre-infection intervention in combination with other
interventions, on HIV incidence and prevalence.
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We begin the study by recapitulating some key historical events that marked the ascendency
of the HIV/AIDS pandemic and PrEP development. Further, we give the motivation of the
research study and provide a brief outline.
1.1 Historical background of HIV/AIDS
The origin of HIV/AIDS infection is still complex with various theories developed and some
in conflict of each other. Some researches documented that HIV/AIDS started in Haiti [1, 2],
while other opinions allegedly claimed that HIV is an experimental man-made and purposely
introduced into the American gay-men community and black African populations as a germ
warfare experiment in 1970s. For some religious people, AIDS as a disease is a curse from God
to punish homosexual individuals and illicit drugs users. However, it is also widely accepted
that HIV/AIDS has originated from animal species: the chimpanzees in Kinshasa, the capital
city of Republic of Zaire, in 1920 [3]. It is believed that HIV was transferred into the human
population by the chimpanzee hunters and consumers who were exposed to animals’ infected
blood [4]. Evidence of disease crossover has been seen available in the case of avian influenza
viruses, bird flu, swine flu and Ebola [5, 6, 7].
Up until 1981, AIDS was classified under rare types of diseases including Pneumocystis carinii
pneumonia (lung infection) [8], Kaposi’s sarcoma (a kind of cancer) [9], and other unknown
deadly diseases that erupted in those years. The first diagnosed patients of Pneumocystis carinii
pneumonia (PCP) and Kaposi’s sarcoma were mostly among men who had sex with other men
(MSM). These patients commonly presented an immune deficiency, exposing them to any op-
portunistic diseases. The PCP syndrome and Kaposi’s sarcoma were often labelled to suggest
that this was related to the gay population in America. For instance, in California and New
York city, the PCP disease was known as gay-related immune deficiency (GRID) [10], whilst
gay-cancer was attributed to Kaposi’s sarcoma. In Africa, in rural areas of Uganda, the PCP
syndrome is known as ‘slim’ disease [11], due to the awful weight loss that presented in most
ill individuals at their symptomatic stage of the disease. However, unlike the predominance
of the syndrome among the gay-men in America, in Uganda the PCP syndrome was reported
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among men as well as women. Thus, PCP and Kaposi’s sarcoma were no longer classified as
being endemic only to gay populations.
In September 1982, in agreement with the international scientific committee, the CDC rede-
fined the GRID syndrome as Acquired Immune Deficiency Syndrome (AIDS) [12]; the first
time the term AIDS was officially used. Many AIDS cases were subsequently reported in dif-
ferent countries across South and North America, Africa, Europe, and Australia. AIDS-related
healthcare organisations were then set up and extensive studies were undertaken by various
group of researchers [13].
In May 1983, health officials in France announced that AIDS could be caused by a virus that
they called Lymphadenopathy-Associated Virus (LAV) [14]. A year later, the National Can-
cer Institute in U.S. working on Kaposi’s sarcoma cancer reported that AIDS was caused by
a virus that they named HTLV-III (human T-cell lymphotropic virus-type III) [15]. In May
1986, the international scientific committee agreed to call the causative virus of AIDS, HIV
(Human Immunodeficiency virus), in place of LAV/HTLV-III [16]. Later, an international
group of researchers reported to CDC that HIV is transmitted via (unsafe) sexual contacts,
infected blood tools (sharing needles or syringes), infected pregnant mother to child (at birth
or through breastfeeding), and during blood transfusion. It was also found that HIV lives off
the blood cells (CD4+ T-cells), which are the human body immune guards.
In March 1987, the first antiretroviral (ARV) drug, zidovudine (AZT), was approved by the
U.S. Food and Drug Administration (FDA) and became the first life-saving medication for
HIV/AIDS treatment [17]. That constituted a great turning point in the fight against HIV
infection spread. Later, several distinct types of ARV drugs were developed and recommended
to be used in a single dose but more preferably in combination of two or three known as an
AIDS ‘cocktail’ and later as HAART (Highly Active Antiretroviral Therapy). HAART use
changed the life expectancy of many individuals living with HIV infection and averted many
AIDS-related deaths. However, HIV cases continued to rise steeply. At the United Nations
(UN) General Assembly in October 1987, many issues including HIV educational campaigns
for global HIV awareness were addressed. As a result, December 1 of each year was declared
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to be the World AIDS Day first commemorated, on 1st December 1988 [18]. Three years later,
the Visual AIDS Artists Caucus launched the Red Ribbon Project to create a visual symbol
to demonstrate compassion for people living with AIDS and their caregivers. The red ribbon
became the international symbol of AIDS awareness [19].
Between 1990 and 2000, the HIV epidemic increased and reached a peak. In July 2002,
HIV/AIDS was classified as the leading cause of death in Africa. Sub-Saharan Africa was
classified (and still is) the worst affected region in the world. In 2013, it was reported that
more than 71% of people living with HIV in world resided in Sub-Saharan Africa [20]. In the
U.S., HIV was prevalent in large U.S. metropolitan areas (82% in 2014), with Baton Rouge,
Miami, and New Orleans topping the list of the areas most heavily burdened [21]. In Asia,
China, India and Indonesia account for about three-quarters of the total number of people
living with HIV.
In 2015, more than 2.1 million people became newly infected worldwide, adding up to a total
of 36.7 million people living with the virus and 1.1 million people died from HIV/AIDS-related
illness [24]. According to recent WHO data, approximately 78 (69.5–87.4) million people have
become infected with HIV, and 35 (29.6–40.8) million have died from HIV/AIDS, since 1981
[24].
1.2 Advances in HIV/AIDS prevention approaches
There are multi-purpose prevention strategies and technologies currently being developed for
effective protection against new HIV infections [22, 23]. In the last 20 years, ARV drugs use has
been helpful in mitigating the endemicity of the HIV pandemic. The recent UNAIDS reported
that 17 million of people living with HIV are receiving ARV treatment [24]. ART programmes
have globally averted an estimated 7.8 million deaths between 2000 and 2014 [25]. ART has
also been a great success in prevention of mother to child transmission . HPTN 052 studies
demonstrated that consistent ARVs uptake by the HIV-positive partner reduces 96% of the
risk of infecting his/her HIV-negative partner [26]. A meta-analysis of 50 publications related
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to discordant couples studies found a 91% reduction in per-partner HIV incidence among cou-
ples using ART [27]. Moreover, risk behaviour change education has contributed greatly in
halting the spread of HIV. Medical male circumcisions have also proven, in many observational
studies, to reduce HIV acquisition by approximately 60% [28, 29]. Female and male condoms
use have been a powerful weapon in the fight against new infections. Governmental health
stakeholders and world health authorities continue to improve the effectiveness of the available
male and female condoms. Recently, the South African government proposed a new type of
male condom to meet the demands of the population [30, 31]. In Gabon, Donatien Mavoungou
with his collaborators presented a drug, namely IMMUNOREX DM28, in the capacity of an
HIV vaccine [32]. Studies are currently being conducted to analyse the rare genes that some
individuals naturally possess and which make them resistant to HIV infection, with a view to
design therapies that confer the same resistance.
More recently, UNAIDS proposed the Fast-Track (the ‘90-90-90’ intervention) treatment tar-
gets, where by 2020, 90% of people living with HIV infection worldwide should be diagnosed,
90% of these diagnosed people should have enrolled in ART, and 90% of people receiving ART
should have a viral load suppressed [33]. Scientists strongly believe that if the ‘triple 90’ strat-
egy is fully adopted worldwide and effectively implemented, total and systematic eradication of
HIV pandemic will be reached by 2030. While many low-income and middle-income countries
are struggling to achieve the ‘triple 90’ goals, Sweden became the first country to achieve these
goals, in September 2016 [34].
1.3 Pre-Exposure Prophylaxis (PrEP)
One of the potential HIV infection prevention measures currently undergoing trials is the use of
ARVs in the form of PrEP. PrEP is a preventive approach against sexual HIV transmission. It
consists of administering ARVs agents to uninfected individuals at high risk of infection. So far,
the biological safety and the effectiveness levels of the PrEP strategy have been explored with
two typical ARVs, namely, Tenofovir Disoproxil Fumarate (TDF) or Truvada (a co-formulation
of TDF and emtricitabine), available in form of a vaginal gel or rectal microbicide, oral pills,
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long-acting vaginal rings, and intramuscular injectables [35, 36]. PrEP trials with both drugs
were carried out (and are still ongoing) in different high risk populations of sexually active men
and women, including stable serodiscordant couples, sex workers, injecting drug users (IDU),
transgenders, and men who have sex with men (MSM), in Africa, Asia, and USA [38, 39, 41].
Results from these trials demonstrated a significant risk reduction in HIV transmission.
The TDF2 studies, launched in Botswana among 1,219 sexually active young adults men and
women showed a 63% efficacy of a consistent daily oral Truvada [38]. In Kenya and Uganda,
the Partners PrEP studies evaluating both TDF and Truvada in 4,758 heterosexual couples
found a 67% HIV transmission risk reduction for a daily oral TDF and 75% for Truvada
[39]. In the iPrEx PrEP trial that targeted MSM and transgender women who have sex with
men, PrEP effectiveness was rated at 44% for daily Truvada intake [37]. In South Africa,
the CAPRISA 004 trial on 889 heterosexual women, reported that regular use of TDF in the
form of a vaginal microbicide gel (1%) lowered HIV incidence by 39% overall and 54% for high
adherence, that is, at least 80% of prescribed doses [40]. Results from a Thai study in IDU
populations indicated that a strict daily oral TDF regimen shrunk HIV transmission odds by
49% [41]. Despite the disparities noticed in the results from these trials, effective protection
is accredited to Truvada use. Thus, in July 2012, the U.S. FDA recommended Truvada for
PrEP use for optimal protection benefits. Several PrEP studies targeting people at risk of HIV
infection transmission exposure in different parts of the world are still underway (see Figure
1.1).
1.4 Upcoming PrEP trials
Numerous ongoing improvement of PrEP interventions including testing new dosing regimens
and new drugs are envisioned. In May 2014, the U.S. CDC released new clinical practice guide-
lines for PrEP. These guidelines addressed the challenges regarding PrEP use in stable serodis-
cordant couples wishing to conceive naturally [43]. New ARVs agents including dapivirine,
rilpivirine, maraviroc, and new integrase inhibitors are under investigation for PrEP use [44].
The ongoing HPTN-069/ACTG-530 trial is assessing the safety of maraviroc as PrEP com-
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Figure 1.1: Planned, Ongoing, and Completed PrEP Evaluation Studies (June 2015) [42].
pared to Truvada protection among MSM, heterosexual men and women, and transgender men
in thirteen cities in USA [45]. The RING and ASPIRE–MTN020 trials in Malawi are evaluating
the Dapivirine intravaginal ring [44]. Phase 1 trials are being conducted of long-acting injecta-
bles which would transform PrEP from daily pill-taking to 3 months injection [46]. Tremendous
new drug formulations and prevention strategies are under development, including gels, films,
long-acting vaginal rings and injectables, and technologies [47, 35]. The PROUD trial [48] in
the U.K and the IPERGAY trial [49] in France are also some of the ongoing PrEP intermittent
dosing studies. The Follow-on African Consortium for Tenofovir Studies (FACTS) 001 trials
is enrolling women aged between 18 and 30 across nine sites in South Africa for another trial
of the TDF 1% vaginal gel. FACTS is assessing the protective benefit of TDF 1% vaginal gel
applied pre- and post-intercourse for HIV and HSV-2 prevention. FACTS 002 is in the planning
phase for a similar trial among adolescent women aged between 16 and 17 [50].
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1.5 Abandoned PrEP trials
Despite the aforementioned great advances in PrEP interventions and HIV infection prevention
measures, some PrEP trials presented limitations and shortcomings resulting early termination.
The FEM-PrEP trial assessing the prevention benefit of daily oral Truvada in Kenyan was
prematurely interrupted due to a lack of protection [51]. The VOICE trail (MTN-003) which
investigated daily TDF vaginal gel among 5,029 heterosexual African women was discontinued
due to its futility [52]. Early PrEP trials have also faced dramatic objections and emerging
protests from activist groups and affiliated non-governmental organisations especially in 2004–
2005. In July 2004, PrEP trial funded by the United States National Institutes of Health and
the Bill and Melinda Gates Foundation in Cambodia was halted due to the increased protests of
activist groups [53, 54]. In 2005, a PrEP trial in Cameroon, led by Family Health International
(FHI), was prematurely interrupted by the Minister of Public Health [54]. Earlier that year,
FHI announced the discontinuation of the ‘fragile’ TDF PrEP trial in Nigeria, due to the lack
of compliance of the required operational and laboratory procedures at the level necessary for
purpose of the study [54]. In a documentary broadcasted on French media and subsequently on
other media, activists speculated that the FHI investigators intentionally exposed participants
to high risk of infection by providing only five counsellors for 400 participants [55]. In May 2005,
a meeting among activists representatives, advocacy and research groups leaders conducted by
the Bill and Melinda Gates Foundation sought resolution by providing deep and comprehensive
information and knowledge about PrEP use benefits.
1.6 Motivation
New approaches to HIV/AIDS prevention and HIV cure are urgently needed to stop the cu-
mulative number of new HIV infections that occur every year across the world. New strategies
as well as prophylactic agents were recently released and tested through different studies to
assess their capacity to suppress the viral load of already-infected individuals or to prevent
the uninfected at high risk of infection. Of these strategies, the PrEP strategy that refers to
8
the use of ARV drugs (Tenofovir or Truvada) before risky sexual exposure is the current HIV
prevention intervention that holds most promise. PrEP strategy is proven in various clinical
trials to reduce the risk of sexual HIV transmission. However, the results obtained from these
studies are complex with diverse findings thereby exposing the need to pursue more investiga-
tions that might give broader insights into the protection benefits of PrEP and provide useful
information for effective implementation of PrEP strategy outside the trial world. While no
conclusive reasons are yet given for the striking differences reported from these trials, consid-
erations focus on adherence levels of PrEP users to the drug and the efficacy of drug. Other
concerns point to the acceptability of the drugs outside the shaped trial zone. Drug resistance
that might jeopardize the therapeutic benefits of PrEP use is also a cause for worry.
PrEP implementation at a population level is gaining much more attention and more research
is needed to better define and determine the required level of adherence to PrEP use, the
preferable dosing of the drugs, affordability of PrEP drug, medical risk of PrEP drugs intake
in long-term use, the impact of drug resistance on PrEP effectiveness, to whom PrEP drug
should be prescribed and when and by whom, the benefit in combining PrEP use with other
effective pre-existing interventions, etc. This project thus seeks to investigate and give more
insights into the impact of these factors in PrEP implementation and PrEP in combination with
other strategies via mathematical modelling. Mathematical models are developed and analysed
incorporating some of the aforementioned factors to give insights into PrEP impact on HIV
incidence and prevalence. PrEP associated with other prevention measures such as early ART
will be considered, and PrEP in combination with risk behaviour change education will be
examined. We expect that the knowledge gained from this study will partially contribute to
better decision making by health stakeholders and the establishment of HIV care policies that
might help to effectively implement PrEP strategies in communities and help in bringing the
HIV pandemic under control.
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1.7 Objectives of the study
The aim of this research project is to formulate mathematical models that can be used to
investigate the impact of PrEP intervention and PrEP interventions used with control strategies
on HIV infection dynamics at a population level.
The primary objectives are
(i) To explore different PrEP intervention scenarios considering distinct levels of adherence
and efficacy in PrEP use at a population level.
(ii) To investigate the impact of combining PrEP intervention and early antiretroviral drug
therapy in the fight against new HIV infections.
(iii) To highlight the relative contribution of PrEP drug resistance in HIV spread and its
impact on the therapeutic benefits of PrEP use.
(iv) To analyse the impact of post HIV educational support service and the effect of time
dependent control (policies) in PrEP intervention through optimal control.
1.8 Outline of the study
This thesis is presented in integrated-articles form that constitute chapter 2, chapter 3, and
chapter 4. Of the first three articles, two are under review while one is accepted with minor
revision.
• In Chapter 2, we formulate a PrEP model to analyse four distinct PrEP interventions
considering PrEP adherence and PrEP efficacy as key control factors. Rigorous mathe-
matical analysis and numerical simulations are carried out and novel model observations
emanating from the model analysis are presented.
• In Chapter 3, factors such as PrEP drug resistance and early antiretroviral use are incor-
porated in the PrEP model for analysis. Mathematical analyses and numerical simulations
are given.
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• In Chapter 4, optimal control theory is applied to a PrEP model while HIV infection
educational support service is incorporated and other important social factors as the
discontinuation of PrEP intake are factored in.
• In Chapter 5, we give a comprehensive conclusion of our findings and recommendations.
1.9 Publications
This thesis is built around the following papers
Chapter 2
• Komi Afassinou, Faraimunashe Chirove and Keshlan S. Govinder (2016), Comparing
strategies of PrEP use and PrEP awareness on HIV infection progression, BioSystems,
(Under review).
Chapter 3
• Komi Afassinou, Faraimunashe Chirove and Keshlan S. Govinder (2016), Pre-exposure
prophylaxis and antiretroviral treatment interventions with drug resistance, Mathemati-
cal Biosciences, (Accepted with minor revision and under revision).
Chapter 4
• Komi Afassinou, Faraimunashe Chirove and Keshlan S. Govinder (2016), Optimizing
PrEP and post-HIV infection control strategies, Journal of Nonlinear Analysis: Real
World Applications (Under review).
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Chapter 2
Comparing strategies of PrEP use and
PrEP awareness on HIV infection
progression
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Comparing strategies of PrEP use and PrEP awareness on HIV
infection progression
Komi Afassinoua,b,∗, Faraimunashe Chirovea, Keshlan S. Govindera
aSchool of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, South Africa
b DST-NRF Center of Excellence in Mathematical and Statistical Sciences (CoE-Mass)
Abstract
We present a compartmental HIV/AIDS model incorporating pre-exposure prophylaxis
(PrEP) use and PrEP efficacy and investigate different strategies capturing the level
of PrEP use and PrEP efficacy. Mathematical analysis is carried out and important
mathematical features of the model such as the epidemic threshold parameter, the
equilibrium points and stability conditions thereof are presented. The threshold pa-
rameter of the model is rigorously analysed and sensitivity analysis is conducted to
get more insights into the HIV infection transmission dynamics in presence of PrEP.
Our results reveal that the model on PrEP use and efficacy is a parameter connected
model where the connecting parameter is dependent on PrEP awareness. The strategy
with high PrEP use and high PrEP efficacy level is shown to be the best but may not
continuously keep the HIV burden under check.
Keywords: PrEP, HIV, PrEP awareness, PrEP efficacy.
1. Introduction
HIV infection prevention by means of abstinence or mutual monogamy practice with
an HIV-negative partner remains the first line of defence against the virus. Although
the method is more effective, it is not fully practised by many individuals in different
communities. Antiretroviral use and correct use of condoms before any sexual activ-
ity were demonstrated to be highly potent and fundamental strategies against HIV
infection. Pre-exposure HIV prophylaxis (PrEP) in general is a healthy preventative
measure for the control of an infection. This includes the use of male/female condoms,
male circumcision, prophylactic vaccines, vaginal and rectal microbicide and systemic
administration of HIV antiretrovirals [1].
PrEP for HIV infection consists of either of microbicide or antiretroviral drugs (ARVs).
We shall focus on the latter when taken by uninfected individuals who are at risk of
getting infected. The benefits of PrEP involves direct protection of PrEP users and
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indirect protection of non-PrEP users leading to reduce numbers of HIV infections due
to decreased transmission [2, 3, 4]. The concept of using ARVs as a preventive method
was successful in prevention of mother-to-child transmission of HIV. It was shown in
animal studies that the proper timing of PrEP use can effectively prevent HIV infec-
tion whilst the inappropriate timing may lead to partial prevention of HIV infection [4].
Recent studies showed that HIV PrEP using ARVs such as Tenofovir/TDF (Tenofovir
Disoproxil fumarate) and Truvada/TDF-FTC (TDF co-formulated with emtricitabine)
substantially reduced the risk of acquiring HIV infection [5]. A large number of clinical
trials have been undertaken (and still undergo) in various heavy HIV affected settings
across the world. Results obtained from these studies have confirmed and spotlight the
potential impact of PrEP interventions on HIV infection incidence. In the iPrEx study
[6], 2,499 HIV-negative men who have sex with men (MSM) were randomly enrolled out
to receive daily oral pill of the fixed-dose combination tablet of emtricitabine and teno-
fovir disoproxil fumarate (that is Truvada) or placebo associated with comprehensive
prevention services provided. The results obtained showed a relative reduction in risk
infection of 44%. Nonetheless, it was demonstrated throughout the studies that in case
of optimal adherence, the HIV incidence could be reduced by 92% [6]. The TDF2 trial
conducted by the Centers of Disease Control investigated the protective efficacy level
of once-daily oral pill of Truvada in 1,219 heterosexual men and women in Botswana
[7] whilst the Partners PrEP trial evaluated the effectiveness of the Tenovofir and Tru-
vada in 4,758 HIV serodiscordant couples in Kenya and Uganda [8]. In Both PrEP
regimen, results showed an effective risk infection reduction by 62% for the Tenofovir
gel whereas Truvada was found 73% effective. The CAPRISA004 study on 899 South
African women showed 39% of risk reduction on HIV acquisition when one considers
TDF gel in form of vaginal gel [9]. In their study the tenofovir gel was recommended to
be applied in the women genital part for two times in a 24 hours period; one dose within
12 hours before sexual acts and another, as soon as possible, within the next 12 hours
after sex [9]. Some argue that one of the great advantage of Tenofovir gel when used by
women is that, women at risk can use it without their partner’s knowledge, avoiding any
systematic objections from the partner. PrEP interventions in HIV infection prevention
potentially had a profound impact and has gained much attention, in the last decade,
around the word [10, 11, 12]. Various clinical trials still undergo phases testing across
the world to refine the existing PrEP use policies and suggest better comprehension
information regarding PrEP use; these trials include MTN VOICE, CAPRISA, TDF2,
Partners FEM-PrEP. Thus, PrEP is likely to be added to the list of the pillars of HIV
comprehensive prevention strategies. Of note, PrEP efficacy and PrEP use awareness
are some of the important factors which affect PrEP intervention. The two factors can
contribute to low prevention or high prevention depending on the strategy used [13].
Mathematical PrEP models analyses in the last years have also supported the poten-
tial role that played PrEP use in HIV infection reduction in communities. Ashrafur
et al. in [13] investigated the impact of Tenofovir gel as a PrEP on HIV infection.
Their results showed that the effectiveness of the gel largely depends on the level of
adherence to the gel and the proportion of women under gel coverage. The authors in
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[14] studied the interactions between PrEP interventions and treatment programs in
resource-constrained countries. Their results spotlighted the potential benefits of PrEP
intervention when a high “quality” of PrEP is taken into account. Visser et al. [4] used
mathematical models to fit data collected from some countries which rolled out PrEP
use in high risk population. Their model captured a certain number of factors affecting
PrEP use such gender, level of risk, state of infection and PrEP intake. To the best
of our knowledge, PrEP awareness and PrEP efficacy have not yet been considered in
mathematical PrEP models analyses. We strongly believe that these two factors need
to be taken into account for an effective PrEP implementation.
In this study, we shall investigate the impact of PrEP strategies involving the level of
PrEP use awareness and the efficacy of PrEP in a community. We shall do this by
testing the benefits of administering the following strategies: (i) low PrEP use and low
PrEP efficacy, (ii) low PrEP use and high PrEP efficacy, (iii) high PrEP use and low
PrEP efficacy and (iv) high PrEP use and high PrEP efficacy. We shall compare the
effects of these strategies to a scenario with no PrEP use at all.
The model formulation shall be presented in section 2, the model essential proprieties in
section 3, model analysis in section 4, numerical simulations in section 5 and discussion
of results in section 6.
2. Model Formulation
We partition the human population into five classes, namely: susceptible non-PrEP
users S, susceptible PrEP users Sp, infected non-PrEP users I, infected PrEP users Ip,
and AIDS individuals A. We assume that all at risk individuals are recruited into the
non-PrEP susceptible class when they are sexually active at constant rate π. Whilst
in this class, individuals are exposed to PrEP use awareness and decide whether or
not to use PrEP as a priority preventative measure. A proportion γ, 0 ≤ γ ≤ 1,
responds positively to PrEP use whilst the remaining proportion, (1−γ), does not. By
responding positively to PrEP use, we mean acceptance and consistence intake of PrEP
drug provided. Individuals who accept PrEP will immediately start using it and move
to the class of susceptible PrEP users and those who do not respond to PrEP use will
remain in the non-PrEP susceptible class. Reasons for not responding to PrEP use span
from cultural and religious beliefs, to inadequate PrEP awareness campaigns amongst
others. The non-PrEP susceptible individuals are removed from this class through
either natural death or through HIV infection due to unsafe sexual practices. PrEP
users are assumed to continue using PrEP until they leave the class. The susceptible
PrEP users move out of their class through either natural death or HIV infection due
to PrEP protection failure. We use PrEP efficacy σ, 0 ≤ σ ≤ 1, as a measure for PrEP
protection. Thus (1 − σ)Sp individuals are exposed to successful HIV infection due to
PrEP protection failure.
Non-PrEP users who become infected with HIV move to a new class of infected non-
PrEP users I through a force of infection λ(I, Ip, A). They leave the class through either











(1 − γ)λS (1 − σ)λSp
ρ1 I
ρ2 Ip
Figure 1: Flow diagram for the pre-exposure HIV prophylaxis model.
due to PrEP protection failure move to the class of infected PrEP users and leave the
class through natural death or progression to the AIDS class A at a rate ρ2. AIDS
individuals die naturally or die due to AIDS at a rate δ. We assume that the natural
death rate µ is the same for all the five classes. We define the total human population
as the sum of all individuals in the five classes as
N(t) = S(t) + Sp(t) + I(t) + Ip(t) + A(t). (1)
We represent our compartmentalized model through the flow diagram in Figure 1.
The change in the flow of individuals in the five classes is governed by the system of
nonlinear ordinary differential equations given by
Ṡ = π − γS − (1 − γ)λS − µS, (2)
Ṡp = γS − (1 − σ)λSp − µSp, (3)
İ = (1 − γ)λS − (ρ1 + µ)I, (4)
İp = (1 − σ)λSp − (ρ2 + µ)Ip, (5)
Ȧ = ρ1I + ρ2Ip − (µ+ δ)A, (6)
where the upper dot represents the derivative of the component with respect to time t.
We consider the force of infection to be
λ(I, Ip, A) =




where η1 < 1 denotes the measure of the impact of the infected PrEP users towards HIV
infection compared to the contribution from non-PrEP infected individuals and AIDS
individuals. A similar explanation is valid for η2 > 1 with regards to the contribution of
AIDS individuals. The probability of a successful HIV infection transmission resulting
from unsafe sexual contact between an infected individual and a susceptible individual
is denoted by c.
3. Positivity and boundedness of the solutions of the model
The time evolution of the population of each class defined is revealed by the solutions of
system (2)-(6). Like any dynamical system, it is important to ensure the well-posedness
of the system so that the solutions reflect the natural phenomenon or the process de-
scribed. Thus, in our case for the solutions of the system (2)-(6) to be biologically
meaningful, we should guarantee the positivity and boundedness of these solutions for
all the time t ≥ 0.
















ψ(t) = π exp
{∫ t
0
























(µ+ γ + (1 − γ)λ(τ))dτ
}
,
where S(0) is a given initial value of S(t). It follows that S(t) is non-negative for all
the time if S(0) is non-negative. This indicates that the population variable S(t) will
remain non-negative for t ≥ 0.
Similarly, the other population variables can be proven non-negative using the corre-
sponding equation of the system. This shows that the solutions of the system (2)-(6)
with non-negative initial conditions will remain non-negative for all time t ≥ 0. We
state this result as follows:
Lemma 1. If the given initial conditions S(0), Sp(0), I(0), Ip(0), and A(0) of the
system (2)-(6) are non-negative, then so are the resulting solutions S(t), Sp(t), I(t),
Ip(t), and A(t) for all the time t ≥ 0.
Moreover, adding all the equations (2)-(6) yields
Ṅ = π − µN − δA
≤ π − µN. (8)
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where N(0) is the initial value of N(t). It can be seen that if N(0) ≤ π
µ
then N(t) ≤ π
µ
for t → ∞. Hence, π
µ
an is upper bound of N(t) and subsequently, for all the solutions
of the system. On another hand, if N(0) > π
µ
then N(t) will decrease to π
µ
as t → ∞,
that is, all the solutions of the system converge to π
µ
as time goes. In both situation, π
µ
is the upper bound of all the solutions. We therefore define the region
Bf =
{





as the biological feasible region of the solutions of our model.
From what precedes, it is clear that all solutions of the system starting in the region Bf
will remain inside for all the time whereas all solutions starting in the neighbourhood of
Bf will enter or approach it asymptotically. The region Bf is thus said to be positively
invariant and biologically tractable, under the flow induced by the system. We shall
therefore confine our model analysis to the region Bf .
4. Model analysis
We carry out the model analysis exploring the stability conditions of the equilibrium
points of the system (2)-(6). We shall use the epidemic threshold parameter R0, that
is, the basic reproduction ratio of our model to establish the stability analysis. Further,
sensitivity analysis of R0 shall be conducted to help identifying policies or intervention
strategies that would be used to reduce HIV infection prevalence when a particular
parameter value is subjected to a perturbation.
4.1. The basic reproduction ratio R0
The basic reproduction ratio of our model is an important threshold that is used to
predict conditions under which HIV infection is most likely to progress or regress in the
presence of PrEP use awareness and PrEP efficacy. The basic reproduction ratio for
the system of equations (2)-(6) is calculated using the next generation matrix method
in [15]. Conforming to the same notations as in [15], the matrices F and V for the new


















 and V =


ρ1 + µ 0 0
0 ρ2 + µ 0
−ρ1 −ρ2 µ+ δ

 .
The basic reproduction ratio of the system defined as the spectral radius of the next
generation matrix (FV−1) is given by
R0 =
cµ(1 − γ)(µ+ δ + ρ1η2)
(γ + µ)(µ+ ρ1)(µ+ δ)
+
cγ(1 − σ)(η1(µ+ δ) + ρ2η2)
(γ + µ)(µ+ ρ2)(µ+ δ)
. (10)
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Epidemiologically, the basic reproduction ratio R0 represents the expected number of
the secondary infections that result from introducing a single infected individual into a
pure susceptible population where PrEP program is implemented.
To get better understanding of the basic reproduction ratio R0, we give biological signif-





cates the average period of time that an infected individual spends in I(t) class and A(t)






are the probabilities that a typical
susceptible individual being infected by an individual in I(t) class and A(t) class, respec-










the proportion of new HIV infections caused by an infected non-PrEP user or AIDS in-
dividual, whilst the factor κ = µ
(γ+µ)
measures the effectiveness of the PrEP awareness.
Clearly, when γ increases, to mean when more susceptible individuals are enrolling in
PrEP use, the factor κ is reduced, therefore R1 is reduced. The infection rate R1 is
therefore reduced when γ increases. In other words, this indicates that the more the
susceptible individuals are on PrEP use, the more the infection rate R1 is reduced.
A similar relevant significance can also be given to each term in second component









models the proportion of new
HIV infections caused by an infected PrEP user and AIDS individual.
Upon giving these analyses, we re-write the basic reproduction ratio R0 in terms of R1,
R2, and κ to obtain
R0 = κR1 + (1 − κ)R2, (11)
where
• R1 models the proportion of new infections caused by a non-PrEP infected indi-
vidual and an AIDS individual, whilst
• R2 models the proportion of new infection caused by a PrEP infected individual
and AIDS individuals, and
• κ measures the effectiveness of the PrEP awareness.
We shall define Rslow = min{κR1, (1 − κ)R2} as the slow reproduction ratio and
Rfast = max{κR1, (1− κ)R2} as the fast reproduction ratio. Thus, we call the param-
eter κ (0 < κ ≤ 1), the slow-fast parameter. The PrEP model (2)-(6) is said to be a
parameter connected model.
Definition 1. An epidemiological model
(S) : ẋ = f(x), x ∈ Rn+
is said to be a parameter connected model, if there exists a partition of that model
into two sub-models (S1) and (S2) such that the basic reproduction ratio of the model
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(S) connected by a parameter κ, is a linear combination of basic reproduction ratios,
R1 and R2, of the sub-models (S1) and (S2) satisfying
R0 = κR1 + (1 − κ)R2. (12)
Theorem 1. The PrEP model (2)-(6) is parameter connected model.
Proof. A close observation indicates that in a scenario where PrEP is 100% effica-
cious, i.e. σ = 1, the number of infected individuals due to PrEP protection failure is
zero (Ip = 0). As a result, the HIV infection dynamics is restrained to the dynamics
and interactions between the non-PrEP infected, AIDS individuals, and the non-PrEP





Ṡ = π − (1 − γ)c(I + η2A)
N1
S − (µ+ γ)S,
İ = (1 − γ)c(I + η2A)
N1
S − (ρ1 + µ)I,
Ȧ = ρ1I − (µ+ δ)A.
On the other hand, in a scenario where PrEP use awareness is 100% effective, i.e γ = 1,









İp = (1 − σ)
c(η1Ip + η2A)
N2
Sp − (ρ2 + µ)Ip,
Ȧ = ρ2Ip − (µ+ δ)A.
In both sub-models, N1 = S + I + A and N2 = Sp + Ip + A. As early mentioned,
the sub-model (S1) describes interactions and progression dynamics of non-PrEP users
while the sub-model (S2) describes the interactions and progression of PrEP users. It
is easy to show that the biological feasible region of both sub-models are
Ω1 =
{













respectively; which are positively invariant and attractive. The reproduction ratios for
the sub-models (S1) and (S2) are given by
R1 =
c(1 − γ)(µ+ δ + ρ1η2)
(µ+ ρ1)(µ+ δ)
, R2 =
c(1 − σ)(η1(µ+ δ) + ρ2η2)
(µ+ ρ2)(µ+ δ)
,
respectively. Clearly, the basic reproduction ratio R0 is a linear combination of the
reproduction ratios of sub-models (S1) and (S2) generated from the partition of PrEP
model. The reproduction ratios R1 and R2 are connected by a parameter κ. This
completes the proof.
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Table 1: PrEP strategies and characterization of reproductions ratios
Case Strategy Reproduction ratios
(a) Low PrEP use and Low PrEP efficacy R1 > 1 R2 > 1 R0 > 1
(b) High PrEP use and Low PrEP efficacy R1 < 1 R2 > 1 R0 > 1
(c) Low PrEP use and High PrEP efficacy R1 > 1 R2 < 1 R0 > 1
(d) High PrEP use and High PrEP efficacy R1 < 1 R2 < 1 R0 < 1
Remark 1. The analysis of the parameter connected model for an epidemiological
disease is important in the sense that it reveals that the control of infection in a com-
munity may need a balance in more than one intervention strategies. Thus in our case,
the control will be done by simultaneously monitoring both fast reproduction ratio and
the slow reproduction ratio to levels where the epidemic can be managed effectively.
Moreover, the parameter connected model allows us to determine the group of indi-
viduals in a community who are more susceptible to infection and use the information
to channel intervention strategies equitably. A scenario revealing R1 > 1 > R2, for
instance, indicates that the PrEP use awareness is at low level while the PrEP efficacy
level is at high level. In that particular situation, efforts need to be done to bring
the reproduction ratio associated to the fast reproduction ratio (i.e R1 in this case)
under unity or to the convenient level by enhancing the PrEP awareness scopes. In a
reverse scenario, efforts will be done to improve the PrEP efficacy level. In Table 1,
we present some hypothetical scenarios corresponding to different possible values of the
reproduction ratios.
4.2. Analysis of R0
The basic reproduction ratio of our model captures most of the parameters related to
the social factors captured in our model. Thus, a small variation of the magnitude of
the basic reproduction ratio is simply a result of a small perturbation of conditions
that connect the infection dynamics to one or more of its these parameters. Thus,
performing the sensitivity analysis of R0 with respect to its dependent parameters
seems to be crucial for a deep understanding of the HIV infection dynamics in the
presence of PrEP intervention. Meanwhile, we shall investigate the impact of the PrEP
control parameters, γ and σ, on the basic reproduction ratio.
4.2.1. Impact of γ and σ on R0
We investigate the effects of PrEP awareness and PrEP efficacy on R0 by computing

















< 0 for R2 ≤ R1, γ 6= 1, (13)
∂R0
∂γ






R1, γ 6= 1, (14)
∂R0
∂γ









< 0, σ 6= 1. (16)









R0 = κR1, (18)
lim
(σγ)→(1,1)
R0 = 0. (19)
Remark 2. From equation (13), we observe that an increase in PrEP awareness can
lead to a reduction of the basic reproduction ratio as long as the infection rate due
to infected PrEP users is less than that of infected non-PrEP users. This strategy
may require the PrEP efficacy to be maintained high in light of equation (17). This
is evident in conditions (17) and (18) where increasing either PrEP awareness only or
PrEP efficacy only will reduce and not eradicate the contribution of infected non-PrEP
users and/or infected PrEP users towards the progression of HIV infection. Results
(13) and (16) also suggest that both PrEP awareness and PrEP efficacy need not be
100% to achieve significant reduction of the basic reproduction ratio. Condition (19)
reveals the same but suggests that to significantly reduce the basic reproduction ratio,
high levels of PrEP awareness and PrEP efficacy need be employed. Conditions (14)
and (15) give a potential warning in the use of PrEP awareness that raising awareness
on prophylaxis alone as a strategy may not always work. Efforts should be made to
consider the efficacy of PrEP as well.
4.2.2. Sensitivity analysis of R0
The sensitivity analysis assesses the amount and the type of change inherent in R0
when a typical dependent parameter value increases or decreases. The normalized
forward sensitivity index methods is one amongst many available methods. This helps
classifying the parameters with respect to their impact on the HIV prevalence and
schedule control strategy accordingly. We shall use parameters values in Table 2 to
compute the magnitude of each index. From [18], the normalized forward sensitivity

















Table 2: Table of parameter values and their description
Parameter Description Value(yr−1) Source
π Recruitment rate 1,084,397 [19]
γ PrEP awareness level 0.72/[0, 0.99] [9]
σ PrEP efficacy level 0.85/[0, 0.99] [13]
µ Natural death rate 0.0163 [19]
ρ1 Progression rate from I class to A class 0.0740 [19]
ρ2 Progression rate from Ip class to A class 0.060 Assumed
δ Disease induced death rate 0.3190 [19]
η1 Transmission rate per act with Ip individual 0.0219 [13]
η2 Transmission rate per act with A individual 1.240 Assumed























The parameters with positive sensitivity index will increase the magnitude of R0 when
their value increases, whereas parameters with negative sensitive index will decrease the
magnitude of R0 when their value increases. Thus, it follows that an increase in the
values of γ, σ, ρ1, ρ2, µ, and δ will lead to a decrease in value of R0 while an increase in
the values of c, η1 and η2 will lead to an increase in the value of R0. However, for human
ethical principle, increase purposely the natural mortality rate (µ), the rate of death
related to AIDS (δ), and the progression rates of infected individuals to AIDS (ρ1 and
ρ2) in order to decrease the value of R0 is not scientifically recommended. It therefore
follows that the PrEP efficacy level σ is the most sensitivity parameter, followed by
the proportion of individuals on PrEP use γ, then contact rates c, η2, and η1, on the
infection dynamics. These results highlight the importance of PrEP awareness and
PrEP efficacy level in reducing HIV infection spread in a community.
4.2.3. Contour plots of R0
The simulation result of R0 as function of γ and σ in form of contour plots in Figure 2
gives more information about the different proportion of γ and σ for an effective HIV
incidence reduction. The simulation indicates that if at least 32% of the susceptible
individuals (at risk of HIV infection) in the study community are enrolled in a con-
sistence PrEP use while the PrEP efficacy level is ranged between 85–100%, then new
HIV infections will be effectively controlled; which may further leads to a substantial
eradication of the disease in the community.
4.3. Model equilibrium points
The system (2)-(6) has two equilibrium points, the disease free equilibrium (DFE) point
E0 and the endemic equilibrium point Ē, which are obtained by equating the right-hand
11
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Figure 2: Simulation of the basic reproduction ratio R0 as function of the control parameters γ and σ
in form of contour plots using parameters values in Table 2.








, 0, 0, 0
)
, (20)
and the endemic equilibrium point given by




γ + (1 − γ)λ∗ + µ,
S̄p =
γπ(
µ+ (1 − σ)λ∗
)(












γ + (1 − γ)λ∗ + µ
)(













(ρ2 + µ)(µ+ (1 − σ)λ∗)
)
,
where λ∗ is a positive solution to the quadratic equation
λ∗2 − a1λ∗ + a0 = 0, (22)
where
a1 =
δρ1µ(1 − γ) + ρ2δ(ρ1 + µ)
(µ+ ρ1 + δ)
+
R1(ρ1 + µ)(µ+ δ)(1 − σ)
(1 − γ)(µ+ ρ1 + δ)
,
a0 =
(µ+ γ)(µ+ δ)(ρ1 + µ)
(1 − γ)(1 − σ)(µ+ ρ1 + δ)
(1 − R0) .
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The quadratic equation (22) has a unique positive real solution λ∗ > 0 when a0 < 0,
that is R0 > 1. Thus λ∗ > 0 corresponds to a unique endemic equilibrium point. Hence,
we state the following:
Theorem 2. The endemic equilibrium point of model (2)-(6) exists and is unique when-
ever R0 > 1.
4.4. Stability analysis of the equilibrium points
Theorem 3. The disease free equilibrium point of model (2)-(6) is globally asymptoti-
cally stable when R0 < 1.
Proof. Following Van den Driessche and Watmough’s technique [15], it suffices to
consider the stability of the matrix F − V where
F − V =


cφ1 − (ρ1 + µ) cη1φ1 cη2φ1
cφ2 cη1φ2 − (ρ2 + µ) cη2φ2
ρ1 ρ2 −(µ+ δ)

 ,
φ1 = (1 − γ)κ, φ2 = (1 − σ)(1 − κ).
The eigenvalues of the matrix F − V are roots of the characteristic equation
λ3 + b2λ
2 + b1λ+ b0 = 0 (23)
where
b2 = (δ + µ) + (ρ1 + 2µ+ ρ2)(1 − R0) + (ρ1 + µ)(1 − κ)R2 + (ρ2 + µ)κR1
+
η2(κρ1 + (1 − κ)ρ2)
µ+ δ
,
b1 = [(µ+ ρ1)(µ+ ρ2) + (µ+ δ)(ρ1 + ρ2 + 2µ)](1 − R0)
+(µ+ δ)(µ+ ρ1)(1 − κ)R2 + (µ+ δ)(µ+ ρ2)κR1
+
cκ(1 − γ)ρ1η2(ρ2 + µ)
(µ+ δ)
+
c(1 − κ)(1 − σ)ρ2η2(ρ1 + µ)
(µ+ δ)
,
b0 = (µ+ δ)(µ+ ρ1)(µ+ ρ2)(1 − R0).
Clearly b0, b1, b2, and b1b2 − b0 given by
b1b2 − b0 = (µ+ δ)C1 + C2C1 + C2(µ+ ρ1)(µ+ ρ2)(1 − R0),
where
C2 = (ρ1 + 2µ+ ρ2)(1 − R0) + (ρ1 + µ)(1 − κ)R2 + (ρ2 + µ)κR1
+
η2(κρ1 + (1 − κ)ρ2)
µ+ δ
,
C1 = (µ+ δ)(ρ1 + ρ2 + 2µ)(1 − R0) + (µ+ δ)(µ+ ρ1)(1 − κ)R2
+(µ+ δ)(µ+ ρ2)κR1 +
cη2
(µ+ δ)
(ρ1φ1(ρ2 + µ) + ρ2φ2(ρ1 + µ)) .
13
are positive whenever R0 < 1. The Routh-Hurwitz criterion for stability [16] is satisfied
when R0 < 1. This means that all the eigenvalues of the matrix F−V are either negative
or have negative real parts whenever R0 < 1. The local stability of the disease free
equilibrium is therefore ensured. Nevertheless, this might not hold when one varies the
initial conditions, otherwise the DFE is globally asymptotically stable.
To guarantee the global stability of the DFE point, we follow Castillo–Chavez et al
technique in [17] to re-write system (2)-(6) in the form
Ẋ = F (X, Y ), (24)
Ẏ = H(X, Y ), H(X, 0) = 0, (25)
where the components of the vector X = (S, Sp) ∈ R2+ denote the uninfected com-
partment and the components of the vector Y = (I, Ip, A) ∈ R3+ denote the infected
compartments. Thus, the DFE becomes E0 = (X
0, 0) where









The global stability property of the DFE is achieved when the following two conditions
are satisfied:
H1 : For Ẋ(t) = F (X
0, 0), X0 is globally asymptotically stable.









cφ1 − (ρ1 + µ) cη1φ1 cη2φ1
cφ2 cη1φ2 − (ρ2 + µ) cη2φ2
ρ1 ρ2 −(µ+ δ)

 ,
F (X0, 0) =
(
π − (µ+ γ)S0 − αS0p
γS0 − (µ+ α)S0p
)
, and


















(1 − σ)(cI + cη1Ip + cη2A)
(









To prove condition H1, we observe that lim
t→∞
X(t) = X0; thus X0 is globally stable.
That means X(t) converges to X0, independently from the initial conditions.
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To prove condition H2, we require that Ĥ(X, Y ) ≥ 0 that is Ĥ1 ≥ 0 and Ĥ2 ≥ 0.





and 1 − κ < Sp
N
. (27)




, that is N < S + Sp, (28)
which is a contradiction to the fact that S + Sp ≤ N. Therefore Ĥ1 ≥ 0 and Ĥ2 ≥ 0.
This guarantee the global stability of the DFE.
In summary, we note that independently of the given initial conditions, the DFE point
will (globally asymptotically) remain stable whenever R0 < 1. In epidemiological
meaning, this suggests that the HIV infection dynamic will remain under check or will
be effectively controlled once the infection threshold magnitude is kept under unity.
Theorem 4. The endemic equilibrium point of model (2)-(6) is globally asymptotically
stable when R0 > 1.
The proofs of Theorems 3 and 4 are standard, so omitted.
Proof. To analyse the local stability of the endemic point of model (2)–(6), we use
centre manifold theory [17] by introducing the new variables x1 = S, x2 = Sp, x3 = I,
x4 = Ip, x5 = A so that system (2)-(6) becomes
ẋ1 = π − γx1 − (1 − γ)
c(x3 + η1x4 + η2x5)x1
x1 + x2 + x3 + x4 + x5
− µx1, (29)
ẋ2 = γx1 − (1 − σ)
c(x3 + η1x4 + η2x5)x2
x1 + x2 + x3 + x4 + x5
− µx2, (30)
ẋ3 = (1 − γ)
c(x3 + η1x4 + η2x5)x1
x1 + x2 + x3 + x4 + x5
− (ρ1 + µ)x3, (31)
ẋ4 = (1 − σ)
c(x3 + η1x4 + η2x5)x2
x1 + x2 + x3 + x4 + x5
− (ρ2 + µ)x4, (32)
ẋ5 = ρ1x3 + ρ2x4 − (µ+ δ)x5. (33)
Considering c as the bifurcation parameter when R0 = 1 and solving for c, we obtain
c = c∗ =
(µ+ γ)(µ+ δ)(ρ2 + µ)(ρ1 + µ)
µ(1 − γ)((µ+ δ) + η2ρ1)(µ+ ρ2) + γ(1 − σ)(η1(µ+ δ) + η2ρ2)(µ+ ρ1)
.
The Jacobian matrix of the system of equations (29)-(33) evaluated at the DFE E0




−µ− γ 0 −c∗φ1 −c∗η1φ1 −c∗η2φ1
γ −µ −c∗φ2 −c∗η1φ2 −c∗η2φ2
0 0 c∗φ1 − ρ1 − µ c∗η1φ1 c∗η2φ1
0 0 c∗φ2 c∗η1φ2 − ρ2 − µ c∗η2φ2





It is easy to see that zero is a simple eigenvalue of the Jacobian matrix M∗. Thus, one
can apply the centre manifold theory to determine the local stability of the endemic
equilibrium point Ē. The right eigenvector associated with the zero eigenvalue of the
matrix M∗ is given by








(µ+ ρ1)(1 − κ)(κ(1 − σ) + (1 − γ))
µκ(1 − σ) ,
y3 = 1,
y4 =
(1 − κ)(1 − σ)(ρ1 + µ)








(1 − κ)(1 − σ)(ρ1 + µ)
κ(1 − γ)(ρ2 + µ)
.
The left eigenvector associated with the zero eigenvalue of M∗ is given by














To compute the bifurcation coefficients Υa and Υb defined in [17], we reconsider system
(29)-(33) to be in form dX
dt
= f = (f1, f2, f3, f4, f5)

























= −(1 + η1)ακ,
∂2f3
∂x3∂x5









= −(η1 + η2)ακ,
∂2f4
∂x3∂x4
= −(1 + η1)β(1 − κ),
∂2f4
∂x25
= −2η2β(1 − κ),
∂2f4
∂x4∂x5
= −(η1 + η2)β(1 − κ),
∂2f4
∂x23
= −2β(1 − κ),
∂2f4
∂x24
= −2η1β(1 − κ),
∂2f4
∂x3∂x5










5 + (1 + η1)y4 + (1 + η2)y5 + (η1 + η2)y4y5
)
< 0.
The coefficient Υb is obtained from the following non-vanishing partial derivatives
∂2f4
∂x5∂c∗
= (1 − κ)(1 − σ)η2,
∂2f3
∂x4∂c∗
= κ(1 − γ)η1,
∂2f3
∂x5∂c∗
= κ(1 − γ)η2,
∂2f4
∂x3∂c∗
= (1 − κ)(1 − σ), ∂
2f4
∂x4∂c∗
= (1 − κ)(1 − σ)η1,
∂2f3
∂x3∂c∗
= κ(1 − γ),
so that
Υb =
(1 − γ)(1 + η1y4 + η2y5)
R1
> 0.
The bifurcation coefficients Υa < 0 and Υb > 0, the endemic equilibrium point is
therefore locally asymptotically stable.
In light of what precedes, it follows that around the bifurcation point R0 = 1, the
infection dynamics undergoes an exchange of stability, that is, before the bifurcation
point, that is when R0 < 1, the disease free equilibrium point is locally asymptotically
stable and after the bifurcation point, that is when R0 > 1, the DFE point becomes
unstable and the endemic equilibrium point is locally asymptotically stable. The model
therefore exhibits a transcritical bifurcation which is a supercritical bifurcation at R0 =
1. Moreover, in view of the uniqueness, the existence and the local stability conditions
of the endemic equilibrium point obtained from Theorems 1 and 3, it follows that the
endemic equilibrium point is globally asymptotically stable for R0 > 1.
5. Numerical simulations
In this section, we carry out numerical simulations using Python programming language.
We shall determine the initial conditions of the PrEP model and estimate the parameter
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values based on the HIV report from South Africa [19]. We will use initial conditions and
parameter values to investigate the benefits from different possible PrEP intervention
strategies. The results from the simulations based on the strategies will be used to
find the best strategies that are viable for effective PrEP administration and possible
HIV/AIDS burden reduction.
5.1. Parameter estimation
We are guided by the recent South Africa national report on HIV burden [19] for esti-
mation of some the parameters not found in literature. We shall also use the report to
determine the initial conditions based on the South Africa population statistics. People
who qualify for PrEP use are sexually active and hence from the report we consider the
population of individuals aged between 15 and 49 years. The population of individuals
at risk of HIV between 15 to 49 years from the report was 28,907,999. This gives the
initial condition for the susceptible population as S(0) = 28, 907, 999. Individuals living
with HIV were 5.51 millions of whom 16.8% are aged between 15 and 49 years; this
gives I(0) = 925, 680. Since, apparently, there is no use of PrEP in the population,
we assume that Sp(0) = Ip(0) = 0. The data does not distinguish between individu-
als living with HIV from those living with AIDS. Thus the impact of infectious and
AIDS individuals will be judged from the effects of I(0). This leads us to assume that
A(0) = 0.
From the report [19], 1,084,397 individuals at risk aged between 15 to 49 years mi-
grated into the population per year. The individuals join the non-PrEP susceptible
individuals. This gives π = 1, 084, 397. The current life expectancy for South Africa
is 59.1 years for males and 63.1 years for women. We take the life expectancy to be
between 59.1 to 63.1 years. The natural death rate is then defined as the reciprocal
of the life expectancy. Hence, µ ∈ (0.0158, 0.0169). For our numerical simulations, we
considered µ to be the midpoint of the range so that µ = 0.0163, which translates to
a life expectancy of 61.10 years. In addition 31.9% of the individuals living with HIV
were reported to have died of AIDS per year. This yields δ = 0.319. On average, it
was reported that an individual not on any treatment takes between 10.5 to 13.5 years
to develop AIDS. The rate of progression from infectious HIV status to AIDS status is
1/ρ1 so that ρ1 ∈ (0.0740, 0.0952); we shall take ρ1 = 0.0740. We assume that, unlike
the non-PrEP infected individuals, the PrEP infected individuals (due to the PrEP
drugs concentration in their blood) might take more years before developing full blown,
i.e. ρ2 < ρ1. We take ρ2 = 0.060, corresponding to 16.5 years. In [19], the authors esti-
mated the HIV infection transmission rate from an infected individuals to a susceptible
individual on Tenofovir gel by 0.0219. Without portraying a generality, we consider
η1 to be the same, i.e η1 = 0.0219. As early considered η1 < 1 < η2, we assume that
η2 = 1.240. The parameters values are presented in Table 2 with the corresponding
sources.
A study in [9] analysing the impact of Tenofovir gel as PrEP on HIV considered the
use of PrEP efficacy below 50% to have low HIV infection prevention and the efficacy
above 50% to have high HIV infection prevention. We use the same assumptions on
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both PrEP use awareness and PrEP efficacy. We therefore consider four hypothetical
scenarios associated with PrEP use and PrEP awareness and determine the one that
works best. These are, as earlier on stated in section 1, (i) low PrEP use and low PrEP
efficacy, (ii) low PrEP use and high PrEP efficacy, (iii) high PrEP use and low PrEP ef-
ficacy and (iv) high PrEP use and high PrEP efficacy. In our simulations γ = σ = 0.35
for low PrEP use and low PrEP efficacy and γ = σ = 0.85 for high PrEP use and
high PrEP efficacy in view of characterization of low and high efficacy in [9]. While we
acknowledge that any changes in the values of γ and σ may result in changes in the
curves, the qualitative behaviour of the curves are maintained.
5.2. Simulations
The numerical simulation results for our model are represented in Figures 3(a)-(f).
Figures 3(a)-(e) shows the efficacy of the four PrEP strategies on the state variables
whilst Figure 3(f) shows the corresponding prevalence for each strategy.
Figure 3(a) shows an earlier decline in non-PrEP susceptibles at high risk of infection
due PrEP use and PrEP efficacy. This change is associated with the increase in number
of PrEP susceptibles . Unlike the other three PrEP strategies, which show a decline
in numbers of PrEP susceptibles after the first five years, the strategy with high PrEP
use and high PrEP efficacy demonstrate a steep increase of PrEP users over the study
period (Figure 3(b)). We thus note that to maintain more people free of infection, the
best strategy is to implement high PrEP use and high PrEP efficacy.
Application of this latter strategy predicts, in Figure 3(c), a great decrease in number
of new HIV infections in the non-PrEP infectives population, which tends to zero.
Moreover, in the PrEP infectives population, strategy with high PrEP use and low
efficacy is shown, in Figure 3(d), to be the worst strategy. This is characterised by
a switching dominance. This gives a warning on PrEP efficacy level if PrEP is to be
delivered. Thus, we note that the worst strategy is administrating high PrEP use and
low PrEP efficacy.
In Figure 3(e), simulation of the AIDS population is represented. We observe some
switching dominance in the strategies for decreasing these populations. We note that
the great decrease of AIDS population is tied to high PrEP use and high PrEP efficacy
strategy. The simulation results of the prevalence, in Figure 3(f), of each strategy
highlight the need of considering PrEP use and PrEP efficacy at high levels if HIV
infection spread is to be effectively controlled.
Overall, we realize that the short term benefits in the use of PrEP are observed to
come from low PrEP use with high PrEP efficacy, whilst the worst strategy comes from
implementing high PrEP use and low PrEP efficacy. However, for a long run, the best
benefit is realized on the high PrEP use and high efficacy, whilst the worst will come
from low PrEP use and low PrEP efficacy.
Our numerical simulation results therefore suggest that the high PrEP use and high
PrEP efficacy can best be used as a strategy to a certain limit but cannot sustain the
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Figure 3: Time evolution of each sub-population defined showing the impact of PrEP use and PrEP
efficacy at different levels.
reduction in HIV/AIDS burden on its own.
In Table 3, we give precise values of the reproduction ratios with the corresponding
levels of PrEP strategies and risk reduction rate by comparing these strategies with the
case where PrEP is not use at all.
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Table 3: Reproduction ratios and PrEP risk reduction compared with no PrEP use case
Case γ σ Rfast Rslow κ R0 Risk reduction (%)
(a) 0.00 0.00 28.20 0.00 1.00 28.20 –
(b) 0.35 0.35 3.96 0.61 0.041 4.78 83%
(c) 0.85 0.35 4.07 0.079 0.017 4.15 85%
(d) 0.35 0.85 0.91 0.81 0.041 1.73 94%
(e) 0.85 0.85 0.94 0.079 0.017 1.03 96%
(f) 0.86 0.86 0.87 0.07 0.017 0.95 97%
6. Discussion
We analysed an HIV model which captured the dynamics of PrEP use and PrEP efficacy
to investigate the potential impact of possible strategies emanating from PrEP use and
PrEP efficacy. Analytical results revealed that the model incorporating PrEP was
a parameter connected model. This means that the model can be subdivided into
two sub-models so that the reproduction ratio of the original model can be expressed
as a linear combination of the reproduction ratios of the two sub-models. One sub-
model was a non-PrEP users model and the other was the PrEP users model. The
parameter connecting the two reproduction ratios was classified as slow-fast parameter.
This parameter was important in our model in sense that it made possible for one to
trace at any time t whether it is the non-PrEP users or PrEP users dominating the
dynamics of HIV infection. Thus the two reproduction ratios were classified as either
slow reproduction ratios or fast reproduction ratios. Our results revealed that the low
PrEP use and low PrEP efficacy, the low PrEP use and high PrEP efficacy and the high
PrEP use and high PrEP efficacy strategies were dominated by the fast reproduction
ratio associated with the non-PrEP users. The high PrEP use and low PrEP efficacy
strategy is the only strategy whose dynamics are controlled by the fast reproduction
ratio associated with the PrEP users (see Table 3). Our results seem to suggest that
even in the presence of PrEP, the non-PrEP proportion of the population can still
dominate the HIV infection dynamics.
Numerical simulations on the four strategies showed that the high PrEP use and high
PrEP efficacy strategy reduces HIV prevalence better than any other strategies whilst
the low PrEP use and low PrEP efficacy strategy was the worst strategy. In the other
scenarios (except that of the high PrEP use and high PrEP efficacy), the prevalence
gradually increases; this implies the following: either the PrEP use awareness and PrEP
efficacy should be improved if not made perfect or PrEP alone as a mono-strategy
cannot be used to manage the HIV burden for a long time. Our results also suggested
that the strategies using high PrEP efficacy with low PrEP use seem to have better
benefits than the one using high awareness with low efficacy. In addition, in most of
the strategies considered, the basic reproduction ratio was above unity although that
was reduced significantly compared with the case where PrEP is not use at all. The
reproduction ratio could only be reduced to below unity whenever the PrEP use and
PrEP efficacy were at least 85% percent. The study in [13] reported that PrEP efficacy
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of at least 80 percent was able to reduce the basic reproduction ratio below unity. Our
results in this study with parameter values from the South African HIV statistics [19]
are in agreement with the result in [13].
Our study presented some of the benefits that come as a result of PrEP use and its
efficacy. We note that the benefits presented here may be affected by several factors.
These include drug resistance where individuals can develop primary and secondary
resistance to PrEP ARVs and development of side effects. PrEP use may also lead to
risky sexual behavior because people may feel protected against HIV infection. The
increase in risky sexual behaviour may have negative effects especially if the low PrEP
efficacy is part of the strategy. Thus PrEP administration needs to be implemented
together with other forms of intervention such as effective use of condoms and post
infection intervention methods such as the use of HAART and home-based care. For
effective implementation of PrEP programs, care should also be taken to minimize costs
of PrEP but maximizing the PrEP benefits.
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1. Introduction 
HIV/AIDS infection has been an unbearable health burden for 
the human population across the world for decades and contin- 
ues to cause massive loss of lives, especially in the resources- 
constrained countries. From the recent data of the World Health 
Organisation (WHO), an estimated 36.7 (34.0–39.8) million peo- 
ple were living with HIV, with 2.1 (1.8–2.4) million newly in- 
fected globally, and 1.1 million deaths due to HIV/AIDS disease 
in 2015 [1] . Effective prevention strategies and potent HIV cure 
medicines are imperatively needed even though many clinical tri- 
als and research studies have already been undertaken (and are 
still on ongoing) throughout the world. The situation has been ex- 
acerbated by the non-adherence to risky behavioural change in- 
terventions such as safe sexual practices, monogamy, and sterilisa- 
tion of blood tools. This is especially prevalent in the young adults 
class and individuals with low literacy. Fortunately, antiretroviral 
drug (ARVs) use has helped in improving the life expectancy of 
already-infected individuals. Globally, 17 million people living with 
HIV were accessing antiretroviral therapy (ART) by December 2015, 
up from 15.8 million in June 2015 [1] . ART programmes have glob- 
ally averted an estimated 7.8 million deaths between 20 0 0 and 
2014 [2] . Consistent and appropriate intake of the HIV life-saving 
antiretroviral drugs by infected individuals was also found to re- 
duce the risk of infecting their sero-negative partners. ART has 
thus played a crucial role in the fight against HIV infection, espe- 
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cially in preventing mother-to-child transmission [3] . Prevention is 
the ideal and most effective strategy to significantly reduce the HIV 
burden. Of course, vaccination would be a very effective preventive 
strategy but, so far, no HIV vaccine is available. 
On July 16, 2012, two ARVs namely Tenofovir and Truvada (a 
co-formulation of Emtricitabine and Tenofovir) were approved by 
the US Food and Drug Administration, for legal prescription by 
medical health experts, in the form of pre-exposure prophylaxis 
(PrEP) [4,5] . PrEP consists of administering the HIV drugs to un- 
infected individuals, particularly to those at high risk of infection. 
PrEP is not an HIV vaccine, but a new preventive approach. Sev- 
eral clinical trials (iPrEx, Partners, TDF2, Caprisa) were launched 
across America, Africa, and Asia, targeting sex workers, injecting 
drug users, men who have sex with men, transgender women, and 
heterosexual women to evaluate the biological safety and the ef- 
fectiveness of the two recommended drugs. Results from these tri- 
als showed that both drugs were sufficiently potent to avert HIV 
infection through sexual intercourse. The iPrEx trial, on men who 
have sex with men (MSM) and transgender women who have sex 
with men, provided evidence that consistent daily oral Truvada in- 
take reduced the risk of HIV infection by 44%. The Partners PrEP 
trial, results showed that the Tenofovir gel reduced the risk of in- 
fection by at least 62% and Truvada’s protection ranged between 
63% and 73% [6] . Results from animals’ studies also confirmed the 
PrEP’s usefulness by providing valuable information about PrEP ef- 
fectiveness [7,8] . Thus, PrEP has become an ideal and promising 
preventive intervention for the HIV pandemic. 
PrEP intervention studies have encountered various challenges 
and suffer from some limitations. These include devising an im- 
plementation strategy for effective PrEP awareness enabling max- 
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imum enrolment of the targeted individuals, the efficacy level of 
PrEP drugs for optimal protection, and the PrEP drugs’ resistance 
which results from PrEP use by already-infected individuals. Evi- 
dence has showed that maximum protection via PrEP for HIV in- 
fection depended on the percentage of the daily doses of PrEP 
drugs taken by an uninfected individual. If taken properly this re- 
duced HIV incidence by 92% [9] . The adherence level of PrEP drugs 
is actually a result of the quality of the PrEP awareness campaign. 
The PrEP adherence level may thus be regarded as a measure of 
the PrEP awareness level. 
The efficacy of drugs is generally an important factor in any 
health program roll out. Before Tenovofir and Truvada were in- 
troduced, Garcia–Lerma et al. [8,10] assessed PrEP efficacy levels 
through rhesus macaque models of simian human immunodefi- 
ciency virus infection. For the same purpose, Van Rompay et al. 
[11] looked into PrEP efficacy issue. Their results revealed that 
PrEP may be less protective against infection with drug-resistance 
viruses than against infection with wild-type viruses. Later, the 
FEM-PrEP trial with Truvada-based PrEP, in Kenya, and the VOICE 
trial with Tenofovir-based PrEP, in heterosexual African women, 
were discontinued due to the uncertainty of the drug protection. 
Thus PrEP efficacy levels should not be ignored when assessing 
PrEP effectiveness on HIV infection control. As a result, we include 
PrEP efficacy as one of the key control factors in this study. 
PrEP drug resistance is thus a key factor that weakens the over- 
all effectiveness of PrEP intervention. PrEP resistance emerges from 
two possible scenarios: (i) when an already-infected individual in- 
advertently begins taking PrEP or (ii) when an individual on PrEP 
acquires infection and continues taking the drug. Here, we will 
concentrate on the first scenario. This is due to the fact that this 
commonly occurs with individuals infected in the window period 
before PrEP enrolment and are unlikely to be revealed. Individuals 
willing to be on PrEP (or willing to renew a prescription) are ac- 
tually recommended to go through a pre-randomized test before 
PrEP prescription. However, the available HIV antibody tests can 
not help in detecting infection during the window period [12,13] . 
This may compromise the effective control of HIV infection spread. 
Various mathematical models [14–16] have been developed to 
investigate different aspects of PrEP. Some studies focussed on cal- 
ibrating HIV incidence reduction by ARV therapy [17–19] . Smith 
et al. [20] investigated the impact of antiretroviral resistance on 
HIV infection control for the scenario where PrEP is to be used on 
a massive scale. Bhunu and Mushayabasa [21] assessed the impact 
of using antiretroviral drugs as pre-exposure vaccines. A common 
feature of these studies is that they only considered one control 
strategy (either PrEP or ARVs). We believe that it will be more 
beneficial to combine PrEP and ARV interventions in HIV control. 
We thus formulate an HIV/AIDS model using a system of nonlinear 
ordinary differential equations (ODEs), incorporating PrEP aware- 
ness level, PrEP efficacy, and ARV treatment coverage as key con- 
trol factors. We also incorporate the impact of PrEP drug resistance 
with already-infected individuals on PrEP. In our model analysis, 
the PrEP awareness level will not be distinguished from PrEP ad- 
herence. In addition, we assumed that susceptible individuals who 
adhere to PrEP use will continuously be on PrEP over the study 
period. 
2. Model formulation 
The model describes HIV infection dynamics in a human popu- 
lation of density N ( t ), where PrEP and ARV use are implemented. 
We subdivide the total population into seven sub-populations of 
individuals based on their infection status (susceptible/infected), 
their PrEP use status (on/not on), the period of infection (pre- 
infected/post-infected) when on PrEP, their post-infection care, and 
their infection stage (AIDS). The total population N ( t ) is thus com- 
posed of susceptible individuals who either have never been aware 
of PrEP drug use for HIV prevention or are aware but are not 
convinced of the benefits of PrEP protection but are at substan- 
tial risk of HIV infection ( S ( t )), susceptible individuals on PrEP use 
( S p ( t )), infected non-PrEP users ( I ( t )), pre-infected individuals who 
developed drug resistance under PrEP use due to a false outcome 
of the pre-randomized test ( I p − (t) ), post-infected individuals due 
to PrEP protection failure ( I p ( t )), infected individuals enrolled into 
ARV treatment programs T ( t ), and infected individuals who devel- 
oped full blown AIDS A ( t ). Hence, at time t ≥ 0, the total popula- 
tion is given by 
N(t) = S(t) + S p (t) + I(t) + I p (t) + I p − (t) + T (t) + A (t) . (1) 
All these individuals are considered sexually active and aged be- 
tween 15 and 49 years. Thus, they are assumed to be ma- 
ture enough to receive comprehensive HIV infection preven- 
tion/treatment education. HIV infection dynamics within the popu- 
lation is modelled based on the following assumptions: We assume 
that a proportion γ of susceptible individuals S ( t ) is enrolled in a 
PrEP regimen, whilst the remaining proportion (1 − γ ) indulge in 
behaviour associate with a high risk of HIV infection with no PrEP 
use at a rate λ, where λ denotes the force of infection given by 
λ(t) = cI(t) + cη1 I p (t) + cη2 I p − (t) + cη3 T (t) + cη4 A (t) 
N( t) 
. (2) 
In Eq. (2) , the coefficients ηi , i = 1 , . . . , 4 , represent the transmis- 
sion rates from the corresponding infected individual to a suscep- 
tible individual, while the coefficient c is the average number of 
unsafe sexual acts.We assume that the likelihood of a success- 
ful HIV infection transmission resulting from unsafe sexual con- 
tact between an infected PrEP user ( I p ) and a typical susceptible 
individual is less than that of infected individual in I p − (t) class, 
i.e η1 < η2 (This is due to the drug concentration in their blood 
plasma). Similarly, infected individuals on treatment are assumed 
to be least infectious whereas AIDS individuals are the most in- 
fectious. These assumptions translate to η3 < η1 < η2 < η4 . PrEP 
is not 100% efficacious, so we assume that only a proportion σ of 
the susceptible individuals on PrEP use ( S p ( t )) are protected from 
HIV infection. As a result, the remaining (1 − σ ) S p (t) individuals 
become infected at the rate λ. The parameter σ is hypothetically 
assumed to measure the average efficacy of the PrEP drugs. Of 
those who become infected under PrEP protection, a proportion θ , 
0 < θ < (1 − σ ) , is recognized as being infected before PrEP intake. 
These infected individuals actually present PrEP drug resistance at 
the PrEP post-randomized test. Further, whether they have been 
on PrEP or not, individuals who are detected as HIV-positive at 
the post-randomized PrEP test are enrolled into an ART program 
to ensure that they do not spread the disease further. We assume 
that these individuals seek treatment at an average rate ε, 0 < ε
< 1. Thus, infected individuals in the I ( t ), I p ( t ), and I p − (t) classes 
who enrol into treatment programs are moved to the T ( t ) class, at 
rate ερ i , i = 1 , 2 , 3 , while those who do not and develop AIDS are 
moved into the AIDS class, A ( t ), at the rate (1 − ε) ρi , respectively. 
Here, ρ1 , ρ2 , and ρ3 represent the progression rates of individuals 
out of the I ( t ), I p ( t ), and I p − (t) classes, respectively. We assume that 
individuals on ARV treatment progress to the AIDS class at the rate 
ρ4 (and hence, we assume this is slowest progression rate). Owing 
to their reluctance for HIV infection prevention care, we assume 
that infected individuals in the I ( t ) class may take more time to 
move to the treatment class T ( t ), compared to infected individuals 
in the I p ( t ) class (for whom PrEP education continues to influence 
their decision to undergo treatment). Thus, 1 ρ2 
< 1 ρ1 
. We also as- 
sume that infected individuals in the I p − (t) class will move to the 
treatment class the first before all other infected individuals. This 
translates to ρ3 > ρ2 > ρ1 > ρ4 . All individuals experience natu- 
ral death at the same rate μ, while AIDS individuals die from the 
























(1 − θ)(1 − σ)λ
Fig. 1. The flow diagram of HIV infection dynamics between the sub-populations defined. 
disease at a rate δ. Infection-free individuals are recruited into the 
population via the susceptible class S ( t ) at a constant rate 
. With 
these assumptions, we can schematically represent the movement 
of individuals in the seven sub-populations as indicated in Fig. 1 . 
The mathematical analogue of the figure is given by the following 
system of nonlinear ordinary differential equations: 
˙ S = 
 − γ S − (1 − γ ) λS − μS, (3) 
˙ S p = γ S − (1 − σ ) λS p − μS p , (4) 
˙ I = (1 − γ ) λS − (ρ1 + μ) I, (5) 
˙ I p = (1 − θ )(1 − σ ) λS p − (ρ2 + μ) I p , (6) 
˙ I p − = θ (1 − σ ) λS p − (μ + ρ3 ) I p − , (7) 
˙ T = ρ1 εI + ρ2 εI p + ρ3 εI p − − (μ + ρ4 ) T , (8) 
˙ A = ρ1 (1 − ε) I + ρ2 (1 − ε) I p + ρ3 (1 − ε) I p − + ρ4 T − (μ + δ) A, 
(9) 
with initial conditions S(0) = S 0 , S p (0) = S p0 , I(0) = I 0 , I p (0) = 
I p0 , T (0) = T 0 , I p − (0) = I p −0 , A (0) = A 0 . 
3. Model analysis 
We can now analyse the HIV infection dynamics within the 
population using the system of Eqs. (3) –(9) . In particular, we in- 
vestigate the model’s fundamental properties such as the biologi- 
cal feasible region, the epidemic threshold as well as the equilib- 
rium points and their stability conditions, which are key to the un- 
derstanding the infection dynamics and the impact of the control 
strategies used. 
3.1. The positive invariant region 
The state variables S ( t ), S p ( t ), I ( t ), I p ( t ), I p − (t) , T ( t ), and A ( t ) 
as defined in Table 1 represent human populations and the sys- 
tem of Eqs. (3) –(9) monitors the flow between the seven sub- 
populations. Hence, all the associated parameters are assumed to 
be non-negative. For biological reasons, we need to guarantee that 
all solutions of the system (3) –(9) are positive and will remain pos- 
itive for all the time t ≥ 0. 
We re-write Eq. (3) as 
˙ S ≥ 
 − ((1 − γ ) λ + γ + μ) S, 
Table 1 
Table of variables and their description. 
Variables Description 
S ( t ) Susceptible individuals non-PrEP users 
S p ( t ) Susceptible individuals PrEP users 
I ( t ) Infected non-PrEP users 
I p ( t ) Infected PrEP users 
I p − (t) Already-infected individuals on PrEP use 
T ( t ) Infected individuals on ARVs treatment 
A ( t ) AIDS individuals 







(γ + μ) t + 
∫ t 
0 





(γ + μ) t + 
∫ t 
0 
(1 − γ ) λdτ
}
. (10) 
Integrating both sides of (10) gives 
S(t) exp 
{
(γ + μ) t + 
∫ t 
0 
(1 − γ ) λdτ
}







(γ + μ) z + 
∫ z 
0 










(γ + μ) z + 
∫ z 
0 






−(γ + μ) t −
∫ t 
0 






−(γ + μ) t −
∫ t 
0 
(1 − γ ) λdτ
}]
> 0 . (11) 
Result (11) indicates that the state variable S ( t ) is non-negative 
provided that its initial value S (0) is non-negative. The positiveness 
of the state variable S ( t ) is therefore guaranteed. 
Similarly, it can be shown that the state variables S p ( t ), I ( t ), I p ( t ), 
I p − (t) , T ( t ), and A ( t ) are non-negative provided that their initial 
values S p (0), I (0), I p (0), I p − (0) , T (0) and A (0) are non-negative, re- 
spectively. 
Moreover, adding all the equations of system (3) –(9) gives 
˙ N (t) ≤ 
 − μN(t) . (12) 
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Solving (12) , we obtain 









e −μt , (13) 
from which, we note that N ( t ) converges to 
μ , as t → ∞ . This 
indicates that all solutions of system (3) –(9) are bounded above by 


μ , in a positive region of R 









as the feasible and biologically meaningful region where the exis- 
tence, positiveness, uniqueness, and continuity of the model solu- 
tions hold. We conclude that all solutions of system (3) –(9) , start- 
ing with non-negative values in , will remain non-negative in , 
for all the time t ≥ 0. We therefore claim that the region  is pos- 
itively invariant under the flow induced by the model. We proceed 
to analyse the model in . 
3.2. Equilibrium points of the model and stability analysis 
In this section, we compute the equilibrium points of the model 
and establish their stability conditions. The equilibrium points of 
the model indicate a situation of the infection dynamics within 
the population when no new infection or progression of individ- 
uals from one sub-population to another occur. In other words, at 
the equilibrium point, no change in the size of the sub-populations 
occur with the increase in time. Our model has two equilibrium 
points; the disease free equilibrium point and the endemic equi- 
librium point. 
3.2.1. The disease free equilibrium point and stability analysis 
In the absence of infection, that is, when λ = 0 , the system (3) –
(9) has a disease free equilibrium point (DFE) given by 





(μ + γ ) , 

γ
μ(μ + γ ) , 0 , 0 , 0 , 0 , 0 
)
. (15) 
The stability conditions of the DFE point are explored using the 
control reproduction number [22,23] , which is computed using the 
next generation operator method [24,25] , given by 
R pt = g 1 (g o + (η3 h + g) ρ1 ) 
(ρ1 + μ)(δ + μ) 
+ g 2 (η1 g o + (η3 h + g) ρ2 ) 
(ρ2 + μ)(δ + μ) 
+ g 3 (η2 g o + (η3 h + g) ρ3 ) 
(ρ3 + μ)(δ + μ) 
, (16) 
where g o = (ρ4 + μ)(δ + μ) , g 1 = c(1 −γ ) μ(γ + μ)(ρ4 + μ) , g 2 = 
c(1 −θ )(1 −σ ) γ
(γ + μ)(ρ4 + μ) , 
g 3 = cθ (1 −σ ) γ(γ + μ)(ρ4 + μ) , g = η4 (ρ4 + μ(1 − ε)) , h = ε(δ + μ) . 
The control reproduction number R pt is a threshold quantity 
which measures the ability of the infected individuals to give rise 
to secondary infections when a single infected individual is in- 
troduced into a purely susceptible population (where PrEP and 
ARV use programs are implemented). The parameter R pt is one 
of the key thresholds used to understand the infection dynamics 
and the impact of the control strategies applied. The first term rep- 
resents the contribution of the infected non-PrEP users, individu- 
als on treatment and AIDS individuals through the infection route 
I(t)  T (t)  A (t) in Fig. 1 . The second term represents the con- 
tribution of infected individuals who were not protected by PrEP, 
those infected from the I p ( t ) class on treatment, and AIDS individ- 
uals through the infection route I p (t)  T (t)  A (t) . The last term 
represents the contribution of the already-infected individuals ex- 
posed to PrEP use through the I p − (t)  T (t)  A (t) route. 
From Theorem 2 in [24] , we claim that 
Theorem 1. The disease free equilibrium point of the model is locally 
asymptotically stable when R pt < 1 and unstable otherwise. 
Theorem 1 simply indicates that if the size of the seven sub- 
populations correspond to the coordinates of the DFE point, the in- 
fection can be eradicated from the population under the constraint 
R pt < 1 . In addition, Theorem 1 indicates that, under a small in- 
flux of infected individuals within the pure susceptible population, 
HIV infection will not generate large outbreaks, and will die out 
in time provided that R pt < 1 . However, the infection control may 
not be guaranteed for a large influx of infected individuals into the 
purely susceptible population. To explore conditions under which 
the eradication of the infection is independent of the size of the 
infected populations that flow into the population, we investigate 
the global stability of the DFE point. 
We use the matrix-theoretic method [26] to analyse the global 
stability of the DFE point by defining a function L o ∈ C 1 [, R ] , 
given by 
L o = w  V −1 X, (17) 
where X = [ I, I p , I p − , T , A ]  is a vector of populations from the in- 
fected compartments and w  is the left eigenvector corresponding 
to the eigenvalue ρ(V −1 F ) = ρ(F V −1 ) = R pt of matrix V −1 F , where 
V −1 = 
⎛ 
⎜ ⎜ ⎜ ⎜ ⎜ ⎝ 
1 
ρ1 + μ 0 0 0 0 
0 1 ρ2 + μ 0 0 0 
0 0 1 ρ3 + μ 0 0 
ερ1 
(ρ1 + μ)(ρ4 + μ) 
ερ2 
(ρ2 + μ)(ρ4 + μ) 
ερ3 
(ρ3 + μ)(ρ4 + μ) 
1 
ρ4 + μ 0 
ρ1 (ρ4 + μ(1 −ε)) 
(ρ1 + μ)(ρ4 + μ)(δ+ μ) 
ρ2 (ρ4 + μ(1 −ε)) 
(ρ2 + μ)(ρ4 + μ)(δ+ μ) 
ρ3 (ρ4 + μ(1 −ε)) 
(ρ3 + μ)(ρ4 + μ)(δ+ μ) 
ρ4 








⎜ ⎜ ⎜ ⎜ ⎜ ⎝ 
c(1 −γ ) μ
γ + μ
c(1 −γ ) η1 μ
γ + μ
c(1 −γ ) η2 μ
γ + μ
c(1 −γ ) η3 μ
γ + μ
c(1 −γ ) η4 μ
γ + μ
c(1 −σ )(1 −θ ) γ
γ + μ
c(1 −σ ) η1 (1 −θ ) γ
γ + μ
c(1 −σ ) η2 (1 −θ ) γ
γ + μ
c(1 −σ ) η3 (1 −θ ) γ
γ + μ
c(1 −σ ) η4 (1 −θ ) γ
γ + μ
c(1 −σ ) θγ
γ + μ
c(1 −σ ) η1 θγ
γ + μ
c(1 −σ ) η2 θγ
γ + μ
c(1 −σ ) η3 θγ
γ + μ
c(1 −σ ) η4 θγ
γ + μ
0 0 0 0 0 
0 0 0 0 0 
⎞ 
⎟ ⎟ ⎟ ⎟ ⎟ ⎠ 
. 
We claim that L o is a Lyapunov function provided that R pt < 1 . 
That is, the time derivative of L o is negative definite when R pt < 1 . 
We show this as follows: The time derivative dL o 
dt 
of L o along the 
solutions of system (3) –(9) is given by 
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dL o 
dt 
= w  V −1 dX 
dt 
= w  V −1 [(F − V ) X − R ] 
= w  V −1 (F − V ) X − w  V −1 R 
= (R pt − 1) w  X − w  V −1 R 




⎜ ⎜ ⎜ ⎜ ⎜ ⎜ ⎝ 




γ + μ − S N 
)



















⎟ ⎟ ⎟ ⎟ ⎟ ⎟ ⎠ 
, w  = 
⎛ 











⎟ ⎟ ⎟ ⎟ ⎟ ⎟ ⎠ 
. 
It is easy to see that V −1 > 0 , w  > 0, and R > 0. Thus, the 
first term of dL o 
dt 
is negative, whereas the second term is nega- 
tive when R pt < 1 . Hence, dL o dt < 0 , provided that R pt < 1 . The pro- 
posed function L o is therefore a suitable Lyapunov function for the 
system (3) –(9) that can be used to establish the global stability of 
the DFE point. 
We further note that in case where R pt = 1 (which gives dL o dt = 
w  V −1 R ) the global stability of the DFE point can be investigated 
using LaSalle’s invariance principle [27] by analysing the largest in- 
variant set where dL o 
dt 
= w  V −1 R = 0 . It follows that dL o 
dt 
= 0 im- 
plies R = 0 . This requires λ = 0 or S = μN γ + μ and S p = γ N γ + μ . From 
Eq. (14) , we note that the maximum value of the total population 
is 
μ , that is, N max = 
μ . Thus, S max = 
γ + μ and S pmax = γ
μ(γ + μ) . On 
the other hand, λ = 0 implies I = I p = I p − = T = A = 0 . We there- 
fore deduce that the largest positive invariant subset of  that sat- 
isfies dL o 
dt 
= 0 is the singleton {E 0 } . By LaSalle’s invariance principle 
[27] , the DFE point is globally asymptotically stable when R pt = 1 . 
We summarize these results in the following theorem: 
Theorem 2. The disease free equilibrium point of the model (3) –(9) 
is globally asymptotically stable when R pt ≤ 1 . 
3.2.2. The endemic equilibrium point and stability analysis 
In contrast to the DFE point, the endemic equilibrium corre- 
sponds to the situation in which the infection persists within the 
population. The endemic equilibrium point of system (3) –(9) is 
given by 
E ∗ = (S ∗, S ∗p , I ∗, I ∗p , I ∗p − , T ∗, A ∗) , (18) 
where 









I ∗ = (1 − γ ) 









I ∗p = 
(1 − θ )(1 − σ ) γ









I ∗p − = 
θ (1 − σ ) γ









T ∗ = ερ1 (1 − γ ) 






ερ2 (1 − θ )(1 − σ ) γ
(ρ4 + μ)(ρ2 + μ) 
+ ερ2 (1 − σ ) θγ














A ∗ = ρ1 g 
g o 
(1 − γ ) 








(1 − σ ) γ
(ρ2 + μ) 
+ ρ3 g 
g o 
θ (1 − σ ) γ














with E = (γ + μ) + (1 − γ ) λ∗ and F = μ + (1 − σ ) λ∗. The coordi- 
nates of E ∗ in Eqs. (19) –(25) are determined by equating the sys- 
tem (3) –(9) to zero, and then solved for S ∗, S ∗p , I ∗, I ∗p , I ∗p − , T 
∗, and 
A ∗, respectively. 
For the coordinates of E ∗ to stay in the basin of the feasible 
region , we need λ∗ > 0. To guarantee this we substitute (19) –





EF (a 1 F + η1 a 2 + η2 a 3 + η3 (a 4 F + a 5 + a 6 ) + η4 (a 7 F + a 8 + a 9 )) 


EF (F + γ + λ∗(a 1 F + a 2 + a 3 + a 4 F + a 5 + a 6 + a 7 F + a 8 + a 9 )) 
. 
(26) 
Simplifying Eq. (26) , we obtain the endemic polynomial 
P (λ∗) = λ∗(C 2 λ∗2 + C 1 λ∗ + C 0 ) = 0 , (27) 
where 
C 2 = (1 − σ )(a 1 + a 2 + a 7 ) 
γ + μ , 
C 1 = (1 − σ )(1 − a 1 − a 4 η3 − a 7 η4 ) 
γ + μ
+ μ(a 1 + a 4 + a 7 ) + (a 2 + a 3 + a 5 + a 6 + a 8 + a 9 ) 
γ + μ , 
C 0 = 1 − R pt . 





−4 C 2 C 0 
2 C 2 
; and 
one trivial solution: λ∗3 = 0 . The trivial solution λ∗3 corresponds 
to the DFE point, whilst the positive non-trivial solution λ∗
2 
= 




−4 C 2 C 0 
2 C 2 
corresponds to the endemic equilibrium point. It fol- 
lows that λ∗
2 
> 0 , when C 0 = 1 − R pt < 0 . This implies that E ∗ ex- 
ists in the basin of  whenever R pt > 1 . We summarize this result 
as follows: 
Lemma 1. The endemic equilibrium point E ∗ of the model (3) –(9) 
exists only when R pt > 1 . 
Next, we claim the following: 
Theorem 3. The endemic equilibrium point of the model (3) –(9) is 
globally asymptotically stable when R pt > 1 . 
Proof. To investigate the global stability of the endemic equilib- 
rium point E ∗, we define a function L e given by 
L e = 
7 ∑ 
i =1 
D i L i , D i > 0 , (28) 
where 




, for x i ∈ V = { S, S p , I, I p , I p − , T , A } . 
Clearly, each function L i , i = 1 , . . . , 7 , is positive definite, contin- 
uous and differentiable in . Hence, L e ∈ C 1 [, R + ] . Moreover, 
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equating the first partial derivatives of L e with respect to each x i 
to zero, i.e 
∂L e 
∂x i 
= D i 
(





= 0 , 
yields x i = x ∗i , which means S p = S ∗p , I = I ∗, I p = I ∗p , I p − = I ∗p − , T = 
T ∗, and A = A ∗. It therefore follows that the endemic equilibrium 
point is the only stationary point of the function L e . 
In addition, the second partial derivatives of L e with respect to 
each x i , given by 
∂ 2 L e 
∂x 2 
i 





, i = 1 , . . . , 7 (29) 
are all positive. Hence, the endemic equilibrium is a global mini- 
mum point of the function L e , for all x i ∈  ⊆ R 7 + . 
Now we need to show that L e is a Lyapunov function. For that, 
it suffices to show that the time derivative dL e 
dt 



















is negative definite for all t > 0. We know that for all x i ∈ , dx i dt ≤





i = i 
D i 
(





˙ N . (31) 




μ − N(0) 
)
e −μt . 





i = i 
D i 
(












e −μt . (32) 
We note from Eq. (32) that when the total initial population N (0) 
stays in the basin of , i.e N(0) ≤ 
μ , dL e dt ≤ 0 , as t → ∞ . Other- 
wise, if N(0) > 
μ , the right-hand side of Eq. (31) is negative def- 
inite, therefore dL e 
dt 
≤ 0 . Therefore, regardless of the initial popula- 
tion size N (0), dL e 
dt 
≤ 0 , for all time t > 0. Thus, the proposed func- 
tion L e is a Lyapunov function. L e can be used to prove the global 
stability of the endemic equilibrium point. In addition, we note 
that dL e 
dt 
= 0 if and only if x i = x ∗i , i.e S = S ∗, S p = S ∗p , I = I ∗, I p = 
I ∗p , I p − = I ∗p − , T = T ∗, and A = A ∗. The largest positive invariant sub- 
set of  that satisfies dL e 
dt 
= 0 is the singleton { E ∗} . 
In summary, we note that when R pt > 1 , the system has a 
unique endemic equilibrium point E ∗ in the interior of , which 
is globally asymptotically stable. This completes the proof. 
The analysis of the stability conditions of both equilibrium 
points (indicated in Theorems 2 and 3 ) are to investigate the re- 
sulting state of the infection within the population once one (or 
more than one) of the state variables x i ∈  is subjected to a small 
variation ( εi ), i.e x i −→ x i ± ε i . Such a perturbation may possibly 
shift the corresponding state variable away from its steady state 
value. The local stability tells us that the infection process will re- 
turn back to the steady state on its own if the modified state value 
is near the starting steady state. The global stability shows that the 
infection process can reverse to the steady state (with time) re- 
gardless of the modified state value. From the results obtained, we 
deduce that, unless perturbed, the steady state value of the state 
variables would remain unchanged over time, provided that the in- 
dicated conditions ( R pt > 1 or R pt ≤ 1 ) hold. The model undergoes 
a supercritical bifurcation as shown in Fig. 2 . 
3.3. Analysis of the control reproduction number 
In this section, we investigate the benefit of coupling PrEP in- 
tervention with ARV treatment. We also analyse the impact of the 
Fig. 2. Bifurcation diagram showing a forward bifurcation of λ∗ versus R pt with 
parameter values from Table 2 . 
PrEP resistance rate, θ , on the HIV infection spread using the con- 
trol reproduction number R pt . 
Let R p be the control reproduction number of the model when 
PrEP is effectively implemented as the only control measure. In 
this case, the system (3) –(9) is reduced to six compartments and 
the corresponding control reproduction number R p is given by 
R p = 
g p1 (δ + μ + η4 ρ1 ) 
(ρ1 + μ)(δ + μ) 
+ g p2 (η1 (δ + μ) + η4 ρ2 ) 
(ρ2 + μ)(δ + μ) 
+ g p3 (η2 (δ + μ) + η4 ρ3 ) 
(ρ3 + μ)(δ + μ) 
, (33) 
where g p1 = c(1 −γ ) μγ + μ , g p2 = c(1 −θ )(1 −σ ) γγ + μ , g p3 = cθ (1 −σ ) γγ + μ . 
For the situation where no pre-infected individuals on PrEP are 
detected, i.e θ = 0 , R p becomes 
R po = c(1 − γ ) μ(δ + μ + η4 ρ1 ) 
(γ + μ)(ρ1 + μ)(δ + μ) 
+ c(1 − σ ) γ (η1 (δ + μ) + η4 ρ2 ) 
(γ + μ)(ρ2 + μ)(δ + μ) 
. (34) 
To assess the impact of θ on R p , we compute po p = R p − R po , 
which gives 
po p = 
g p3 μ(η2 − η1 ) 
(ρ2 + μ)(ρ3 + μ) 
+ g p3 μη4 (ρ3 − ρ2 ) 
(ρ2 + μ)(ρ3 + μ)(δ + μ) 
+ g p3 (ρ2 η2 − ρ3 η1 ) 
(ρ2 + μ)(ρ3 + μ)(δ + μ) 
. (35) 
The first two terms of Eq. (35) are positive since we assumed (in 
Section 2 ) that η2 > η1 and ρ3 > ρ2 . Hence, 
po 
p is positive, i.e 







. Parameter η1 (respectively η2 ) represents the trans- 
missible rate of infected individual in I p (respectively I p − ), whereas 
1 
ρ2 
(respectively 1 ρ3 
) represents the average period of time spent in 







the probability that a susceptible individual is infected by an indi- 
vidual I p (respectively I p − ) during his/her infectious period in the 
I p ( t ) (respectively I p − (t) ) class. This result indicates that PrEP drug 
resistance influence on the spread of HIV infection would depend 
on the transmissibility rate and the duration of inadvertent PrEP 
use by already-infected individuals. 
We also investigate conditions under which it is more beneficial 
to undertake PrEP intervention in conjunction with ARV treatment 
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than PrEP intervention alone. We compute p pt = R pt − R p to ob- 
tain 
p pt = 
(
g 1 ερ1 
ρ1 + μ
+ g 2 ερ2 
ρ2 + μ
+ g 3 ερ3 
ρ3 + μ
)(




PrEP and ARV treatment interventions (both concurrently imple- 
mented) will be a more effective intervention in combating HIV 
infection spread than PrEP intervention alone if p pt < 0 , i.e η3 −
η4 μ





δ+ μ < 1 , which gives η3 
< η4 , a condition consistent with the prior assumption made in 
the model formulation. This result simply suggests that PrEP inter- 
vention and ARV use, when implemented concurrently, will mean- 












δ+ μ < 1 predict the challenges 
which might be encountered in a long lasting-control of HIV infec- 
tion with both interventions. 
4. Numerical simulations 
Numerical simulations of the model are performed to support 
the analytical results and also to obtain a broad view of the time 
evolution of the infected populations. The model simulation results 
shall help in validating the potential benefits of PrEP and ARV ther- 
apy when used concurrently or separately in controlling HIV infec- 
tion progression. The contribution of the PrEP resistance rate into 
HIV infection spread will be investigated as well. 
We use the recent WHO and Botswana fourth HIV/AIDS impact 
survey of 2013 [28] for the initial conditions of our model system. 
We target Botswana for our model validation due to the small size 
of the population and their effective handling and implementation 
of HIV health care programs. In 2002, Botswana was one of the few 
sub-Saharan countries capable of providing free ARV therapy to all 
infected individuals seeking treatment. HIV test scopes and ARV 
treatment coverage in Botswana are quite high compared to other 
African countries. From report [28] , 63.7% of the population aged 
15–49 years have had an HIV test and were informed of their HIV 
status. At the end of 2014, there were 34 ART sites and 561 satel- 
lite clinics across the country dispensing ARVs. The national ARV 
census data indicated that there were 247,947 children and adults 
on highly active anti-retroviral therapy (HAART), which translates 
to 63.2% of the total people living with HIV (which is lower than 
69.9% recorded in 2013) [29] . We therefore see Botswana as a good 
and suitable example for effective PrEP implementation alongside 
their existing treatment program. In 2013, the Botswana popula- 
tion was estimated at 2,045,752, within which 1,085,001 adults are 
aged between 15 and 49 years old, of whom 24% are living with 
HIV infection [28] . For our model simulations, we assume the ini- 
tial density of the model sub-populations to be 
S(0) = 1 , 085 , 001 , S p (0) = 0 , I(0) = 263 , 655 , 
I p (0) = I p − (0) = T (0) = A (0) = 0 . 
According to the latest WHO data [30] , life expectancy in 
Botswana is 63.0 years for males and 65.4 years for females, with 
a total life expectancy of 64.2 years, which gives Botswana a world 
life expectancy ranking of 144th. The natural death rate is defined 
as the reciprocal of the life expectancy. Hence, μ = 0 . 015 per year. 
It was also reported that in 2014, HIV/AIDS deaths in Botswana 
reached 5,624, that is 37,61% of total deaths, ranking Botswana 6th 
in the world. This gives δ = 0 . 376 . The current HIV incidence for 
Botswana is documented to be 1.35% [29] . From this same report, 
approximately sixteen percent (15.8%) of women and men aged 
15–49 years have had sexual intercourse with more than one part- 
ner during the 12 months of 2013. This indicates that the aver- 
age number of new sexually active partners acquired per year is 
greater than one. The other parameter values used in our model 
Fig. 3. Simulations of new HIV infections ( I(t) + I p (t ) + I p − (t ) ) for various levels 
of PrEP efficacy and PrEP awareness with constant ART rate ( ε = 0 . 63 ). Parame- 
ter values are taken from Table 2 with (a) ( σ , γ ) varying from 0 to 95%, and 
(b) 0 ≤ γ ≤ 0.95 but with σ fixed at 0.85. 
are indicated and referenced in Table 2 . With these data, we con- 
sider various possible PrEP interventions with distinct proportions 
of sexually active individuals enrolled in PrEP programs with dis- 
tinct PrEP efficacy levels delivered. Unlike other studies, we will 
not distinguish between Tenofovir-based or Truvada-based PrEP in- 
terventions. We will characterise high PrEP awareness when the 
proportion of the susceptible individuals ( γ ) enrolled in PrEP use 
ranges between 90% and 100%, otherwise PrEP awareness will be 
classified as low ( γ < 50%) or moderate (50 ≤ γ ≤ 89%). We vary 
ARV treatment rates from 0% to 63.2% with reference to the report 
[29] . The PrEP resistance rates range from 0 to 7.9% [31] . The sim- 
ulation results are presented in Figs. 3 , 4 and 5 . 
Fig. 3 (a) shows the time evolution of the total new HIV infec- 
tions with different PrEP interventions while ARV treatment is held 
at a constant rate ε = 63% . We observe a significant decrease in 
the peak values of the total new HIV infected individuals when 
PrEP awareness and PrEP efficacy gradually increase. This result 
emphasizes the potential benefits of PrEP intervention when im- 
plemented at higher levels. We also note that the highest peak 
value is reached when PrEP is not applied (i.e only ARV treatment 
is applied). This confirms the necessity of introducing PrEP use in 
high risk communities to address the limitations of ARV interven- 
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Table 2 
Table of parameter values and their description. 
Parameter Description Value (/ yr ) Source 

 Recruitment rate 20,840 Assumed 
γ PrEP awareness level [0, 0.99] [32] 
σ PrEP efficacy level [0, 0.99] [14] 
ε Rate of being put on treatment [0, 0.632] [29] 
θ PrEP resistance rate [0, 0.079] [31] 
μ Natural death rate 0.015 [30] 
δ AIDS related death rate 0.376 [30] 
ρ1 Progression rate out of I ( t ) class 0.074 [33] 
ρ2 Progression rate out of I p ( t ) class 0.060 Assumed 
ρ3 Progression rate out of I p − (t) class 0.080 Assumed 
ρ4 Progression rate from T ( t ) to A ( t ) class 0.052 Assumed 
η1 Transmission rate per act in I p ( t ) class 0.0219 [14] 
η2 Transmission rate per act in I p − (t) class 1.215 Assumed 
η3 Transmission rate per act in T ( t ) class 0.0135 [29] 
η4 Transmission rate per act with A ( t ) individual 1.250 Assumed 
c Average number of unsafe sexual acts 2 [29] 
Fig. 4. Simulations of time variations of the AIDS population, A ( t ), for various ARV 
treatment rates while maintaining a constant PrEP level ( σ = 0 . 95 , γ = 0 . 95 ), and 
PrEP drug resistance ( θ = 0 . 079 ), with other parameter values taken from Table 2 . 
tion in reducing new HIV infections. In comparing the peak values 
for the case when PrEP is not applied (the blue curve), with the 
case when PrEP and ARVs are applied (the green curve), we record 
150,0 0 0 new HIV infections averted in the first half year, a reduc- 
tion of 13%. In addition, our model predicts that when PrEP is im- 
plemented (alongside the ARV treatment) at a high level ( > 92%), 
new infections will immediately decrease from the initial imple- 
mentation time and continuously tend to zero. No peak value is 
observed for that scenario. Our model prediction is thus in agree- 
ment with the characterisation of PrEP effectiveness beyond 92% 
as a high PrEP level in previous studies. 
To stratify the impact of PrEP efficacy from PrEP awareness in 
Fig. 3 (a), we hold all the parameter values unchanged but lower 
the efficacy level from 95% to 85%. The result is presented in 
Fig. 3 (b) which shows that with low PrEP efficacy, a decrease of 
the new infected individuals is probable but over a long time, 
compared to the case when high PrEP efficacy is taken into ac- 
count. This calls for PrEP efficacy pharmacovigilance. In Fig. 4 , we 
vary the ARV treatment rate while maintaining a constant PrEP 
level ( σ = 0 . 95 , γ = 0 . 95 ). We do this to illustrate the total num- 
ber of AIDS individuals over time. The model predicts that the 
number of individuals developing full blown AIDS will decrease 
with an increase of the treatment rate. We note that the highest 
peak is reached when no treatment program is administered (i.e 
only PrEP intervention). This result indicates that PrEP interven- 
tion alone might not fully help in mitigating the endemicity level 
Fig. 5. Simulations of new HIV infections ( I(t) + I p (t ) + I p − (t ) ) for distinct PrEP 
drug resistance rates, 0 ≤ θ ≤ 0.080, with PrEP levels and ART rate held constant. 
Parameter values are taken from Table 2 with (a) σ = 0 . 85 , γ = 0 . 90 , ε = 0 . 63 , and 
(b) σ = 0 . 95 , γ = 0 . 90 , ε = 0 . 63 . 
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Fig. 6. Partial rank correlation coefficients showing the effect of parameter vari- 
ation on R pt . Parameters with positive PRCCs will increase the value of R pt when 
their value is increased, whereas parameters with negative PRCCs will decrease R pt , 
when their value is increased. 
of HIV infection. In other words, our results underscore the impor- 
tance of coupling PrEP intervention and ARV therapy in the fight 
against the HIV pandemic. 
In Figs. 5 (a) and (b), we show the impact of PrEP resistance 
on the cumulative new HIV infections by increasing the value of 
θ from 0 to 0.080. The simulation result presented in Fig. 5 (a) 
shows a significant contribution of the PrEP resistance rate into the 
spread of HIV infection, while PrEP efficacy, PrEP awareness and 
ARV treatment rates are taken at 85%, 90%, and 63%, respectively. 
However, we observe from Fig. 5 (b) that when PrEP efficacy is at 
a high level ( σ = 0 . 95 ), the increase of new HIV infections is quite 
minimal. This simply illustrates that in order to mitigate the con- 
tribution of PrEP resistance to HIV infection spread PrEP efficacy 
needs to be maintained at a high level. 
4.1. Sensitivity analysis 
We performed sensitivity analysis on R pt using Partial Rank 
Correlation Coefficients (PRCCs) with a thousand simulations per 
run to investigate the most influential parameters on R pt . The re- 
sults are presented in Fig. 6 . PrEP efficacy is shown to be the most 
sensitive factor in reducing the value of R pt , while the progression 
rate of infected individuals on treatment to the AIDS stage and the 
average number of risky transmissions per sexual acts are the most 
influential factors in the increase of R pt . 
We also conducted PRCCs and Monte Carlo simulations to ex- 
plore the impact of the variation of parameter values on the 
already-infected PrEP user population. The results are presented in 
Fig. 7 . Parameters with positive PRCCs will increase I p − (t) when 
their value is increased, whereas parameters with negative PRCCs 
will decrease I p − (t) , when their value is increased. These results 
support the earlier findings in Fig. 5 (a) and (b), that an increase in 
PrEP efficacy level has a potent impact in reducing the contribution 
of the already-infected individuals to the HIV infection spread. 
5. Discussion 
In this study, a mathematical model describing HIV infection 
dynamics in an homogeneously mixing population was developed 
to assess the benefit of coupling ARV use for treatment and PrEP 
use for prevention, with drug resistance, in the fight against HIV 
infection progression. The model fundamental properties, such as 
the biological feasible region, the epidemic threshold ( R pt ), the 
equilibrium points, and the stability thereof, were rigorously anal- 
ysed. The analyses indicated that the model has two equilibrium 
Fig. 7. (a) Partial rank correlation coefficients and (b) Monte Carlo simulations of 
one thousand sample values for I p − (t) sub-population versus the PrEP efficacy ( σ ), 
with parameter values given in Table 2 . Parameters with positive PRCCs will in- 
crease the density of I p − (t) when their value is increased, whereas parameters with 
negative PRCCs will decrease I p − (t) , when their value is increased. 
points, the disease free equilibrium (DFE) point and the endemic 
equilibrium point. The DFE point was shown to be globally asymp- 
totically stable when R pt ≤ 1 , whereas the endemic equilibrium 
exists and is globally asymptotically stable when R pt > 1 . The 
model analysis showed that implementation of both strategies in 
communities where high risk of HIV infection prevails reduced HIV 
incidence more significantly than when either strategy is imple- 
mented as a single intervention. Furthermore, numerical simula- 
tions of the model confirmed that combined PrEP and ARV inter- 
vention offers the best potential for substantial new HIV infection 
reduction. In addition, the simulations revealed that for both inter- 
ventions, high adherence is key to effectiveness. The PrEP efficacy 
level was found to be important for effective reduction of new HIV 
infections. The model thus alerts us to PrEP pharmacovigilance if 
PrEP implementation along with ARV therapy is to be effective. In- 
advertent PrEP use by already-infected individuals, which gener- 
ates PrEP drug resistance, was also part of our model analysis. The 
model results showed that an increase in the number of misdiag- 
nosed infected individuals on PrEP could be a key driver of HIV 
infection spread, and is hence a crucial hurdle to curtail HIV infec- 
tion spread by PrEP and ARV use interventions. 
Our model can be modified to include other important factors 
influencing the spread of HIV infections. In particular, we can re- 
fine the epidemiological assumptions made in order to improve 
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the precision of the model outcomes. Appropriate data on PrEP 
and ARV use including PrEP resistance data can be used to im- 
prove model and its outcomes. Discontinuation of PrEP use (result- 
ing from side effects, financial means, unavailability of the drugs) 
can also be incorporated. HIV incidence per gender, cost effective- 
ness, cost benefit analysis and optimal control theory to investi- 
gate whether PrEP use for HIV control should be time independent 
(supply at a constant value) or time dependent (supply according 
to the demand of the time) are also some of the factors that can 
be included for better predictions. 
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Abstract
We present a mathematical model describing HIV infection dynamics in an homo-
geneous population where pre-exposure prophylaxis (PrEP) drugs are accessible and
post-HIV infection support services are scheduled. The model is used to investigate
the benefits of PrEP use as potential HIV infection prevention intervention and post-
infection support services. Thus, PrEP awareness, PrEP efficacy, and post-infection
HIV education are some of the key control factors considered throughout the analy-
sis of the model. The controls are considered time independent while analysing the
endemicity conditions of the infection, and then time dependent to investigate the
optimal efforts and necessary costs needed to mitigate the infection endemicity level
and possible total eradication. The analytical and numerical results obtained suggest
best practice for effective HIV infection eradication through a successful PrEP program
implementation.
Keywords: PrEP efficacy, PrEP awareness, HIV status, optimal control.
1. Introduction
The major transmission routes for HIV infection are: (1) horizontal transmission (dur-
ing unsafe sexual contact), (2) vertical transmission (infected pregnant mother to child
or during breast feeding), and (3) direct injection with contaminated tools (needles,
syringes, knife) during blood transfusion. Transmission through sexual contact remains
the most common transmission mode. This has underscored the importance of inten-
sifying prevention efforts to reduce transmission related to unsafe sexual contact. The
“ABC” strategies (Abstinence, Be faithful to HIV-partner, Condom use), reduction of
the number of sexual partners, sterilisation of all blood tools, and male circumcision
are some of the first intervention strategies against the HIV infection. However, their
implementation has been largely affected by factors such as culture, financial income,
gender inequalities, and inadequate facilities. These behavioural interventions have
thus not universally been able to contain the pandemic. There is a need to have more
effective preventive strategies to contain HIV infection progression. More than 20 an-
tiretroviral drugs (ARVs) are currently available. These drugs, when used properly,
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have a potential to suppress the viral load of the infected patient. This allows the
immune system response to recover and improve its effectiveness against the virus and
subsequently extends one’s lifespan. The ARVs have managed to avert early AIDS
related deaths and significantly reduced the likelihood of HIV infection transmission.
For instance, in serodiscordant couples the risk of infecting the HIV-negative partner
is reduced by between 63% and 73% when the HIV-positive partner is taking ARVs
[1]. In addition, an HIV-positive pregnant mother on consistent antiretroviral therapy
would reduce perinatal transmission. Zidovudine (ZDV) used before, during, and af-
ter delivery reduced vertical transmission rate from 25.5% to 8.3% [2]. Perinatal HIV
transmission prevention has been the most successful HIV prevention strategy to date.
ARVs are also recommended to be taken within 72 hours when one is exposed to the
virus [3]. ARVs have been a reliable means for the treatment of people living with
HIV infection and a potential measure to reduce HIV infection rate. Between 1996 and
2012, ARVs treatment averted 6.6 million AIDS related deaths worldwide, including
5.5 million deaths in low-and middle-income countries [4].
All the aforementioned findings have boosted the hope of possible HIV vaccine finding
and stimulated the concept of prescribing antiretroviral drugs to susceptible individuals
in the form of pre-exposure prophylaxis (PrEP). PrEP is simply a preventive medicine or
preventive care consisting of measures taken to prevent the outbreak of some diseases
rather than curing them or treating their symptoms. PrEP should be distinguished
from post-exposure prophylaxis (PEP), in which an individual takes ARVs soon after a
potential HIV exposure with the goal of reducing the likelihood of infection [5]. PrEP
has been successfully practised for other disease prevention such as malaria, influenza,
and even for birth control. In case of HIV, PrEP is administrated as a daily oral pill or
microbicide gel by susceptible individuals at a high-risk of infection. PrEP is a novel
approach to HIV prevention that is systematically directed to people at high risk such
as commercial sex workers, injecting drugs users, or people for whom consistent condom
use have proven difficult.
In exploring PrEP effectiveness, a large number of clinical trials and studies of HIV
PrEP intervention have been undertaken and works still ongoing in different countries
including Peru, Thailand, Botswana, United States, and Nigeria, etc. Two PrEP drugs
(Tenofovir Fumarate/TDF and Truvada/TDF+emtricitabine) were approved by the
United States Food and Drugs Administration (FDA) for their use in high risk groups
as a form of PrEP. A dose of 300 mg TDF alone or in combination with 200/245mg of
emtricitabine (yielding Truavada) was shown to significantly reduce the risk of sexually
acquisition of HIV infection in men and women. The PrEP drug use for HIV infection
prevention is an additional and promising preventive mode of HIV infection. A healthy
individual keen to be on PrEP use for HIV infection prevention is recommended to be
tested first in order to ensure that he/she is HIV negative. Many individuals are cur-
rently ignorant of their HIV status. Thus, PrEP program when effectively implemented
can play an important role in ongoing efforts for comprehensive HIV prevention and
maximum HIV screening programs as well as proper post-infection monitoring [6].
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Results from some theoretical studies analysing the risk perception of PrEP use and
PrEP effectiveness have brought attention to the level of PrEP adherence as well as
PrEP efficacy level [7, 8, 9, 10]. Rahman et al. [11] developed a HIV/AIDS model
investigating the impact of Tenofovir gel as PrEP on HIV infection. Their simulation
results, fitted with data from South Africa, suggested that the effective reduction of
HIV infection through sexual intercourse depends highly on its adherence and cover-
age. Conway et al. [3] worked on stochastic models based on continuous-time branching
process to analyse the pre- and post-exposure prophylaxis interventions against HIV
infection considering different scenarios. A study by Vissers et al. [12] used a mathe-
matical model to fit data collected from some countries which rolled out PrEP use in
different variable such as gender, level of risk, stage of infection and PrEP adherence is
presented. The results obtained from the analysis suggested that high risk behaviour
reduced the impact of PrEP use. In [13], Mushayabasa highlighted the effects of the
role played by the HIV/AIDS support groups, HIV test and post HIV infection coun-
sellings in combating new HIV infections. The studies in [14] shed light on the impact
of HIV screening of unaware infectives for optimal control and treatment of HIV/AIDS.
Inspired by these previous studies on HIV infection and the PrEP drug use for HIV
infection prevention, we intend in this study to examine and shed light on the impact
of PrEP awareness, PrEP efficacy level, HIV screening and post-infection education
required to alleviate the HIV infection incidence in community using optimal control
theory. We strongly believe that understanding the mathematical behaviour and the
effects in change of the value of these control factors in HIV infection dynamics is very
important.
We organise this article as follows: in section 2, we elucidate the essential dynamics of
the HIV infection within a population where a PrEP program and post-infection edu-
cational service are scheduled, which led to a system of ordinary differential equations
(ODEs) that mathematically model the infection dynamics. In section 3, qualitative
analysis of the model important features is carried out. In section 4, stability conditions
of the model equilibrium points are investigated. In Section 5, optimal control theory
is incorporated into the analysis, using Pointryagin’s maximum principle. In section 6,
numerical simulations are presented with discussion thereof.
2. Model Formulation
We consider a community with a total population of N(t) individuals at risk of HIV
infection at any time t, and where HIV PrEP drugs, voluntary HIV screening, and
post-infection education services are accessible. On the basis of their HIV status and
the health decision taken, the N(t) individuals are subdivided, at time t > 0, into
seven distinct subclasses, namely: susceptible non-PrEP users who do not know their
HIV status S(t), susceptible PrEP users who know their status and decide to enrol
into PrEP drugs administration Sp(t), infected non-PrEP users who do not know their
HIV status Id(t), infected PrEP users who do not know that PrEP has failed to protect
them Idp(t), infected individuals who know their HIV status and who still indulge in
risky sexual activities Ikr(t), infected individuals who know their HIV status and who
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have withdrawn from risky sexual behaviour Ikn(t), and AIDS individuals A(t). We
assume that the AIDS individuals are weak and symptomatic, and therefore considered
sexually inactive. As a result, they do not influence the spread of HIV. In addition,
the population is assumed to be uniform and homogeneously mixed so that the total
population is given by
N(t) = S(t) + Sp(t) + Id(t) + Idp(t) + Ikr(t) + Ikn(t) + A(t). (1)
HIV transmission dynamics in this population is assumed to be through horizontal
transmission, so only sexually active individuals shall be considered in this study. A
successful HIV infection transmission resulting from sexual contact between a suscep-
tible individual and an infected individual from Id(t), Idp(t), and Ikr(t) classes are
assumed to be at the rates η1, η2 and η3, so that η2 < η3 < η1, respectively, and the
force of infection λ is given by
λ =
cη1Id(t) + cη2Idp(t) + cη3Ikr(t)
N(t)
, (2)
where the parameter c represents the average number of new sexually active partners
that each infected individual acquires per unit time. We assume that individuals in Id(t)
and Idp(t) classes are screened for HIV infection at the rate w1 and w2, respectively,
so that w1 < w2. This inequality spans from the fact that in factual PrEP regimen,
PrEP users are more regularly tested than the non-PrEP users. The proportion of
the susceptible individuals on PrEP drug use is assumed to be γ, 0 < γ ≤ 1, where
γ hypothetically measures the PrEP awareness level. The remaining proportion (1 −
γ)S not on PrEP may engage in risky sexual behaviour and become infected at rate
(1 − γ)λ. In addition, we assume that among the susceptible individuals who seek
PrEP protection with consistent adherence to prescription, only a proportion σ get
protected (σ thus measures the PrEP drugs efficacy level), and (1 − σ)Sp individuals
are exposed to HIV infection risk and become infected at the rate (1−σ)λ. Factors such
as waning, side-effects, and financial problems may affect the adherence. Thus, PrEP
users interrupt the intake of the medication and hence move back to the susceptible
class at rate α, where 0 ≤ α ≤ 1, before they become infected. We also assume
that once aware of their HIV status, infected individuals are encouraged to enrol in
HIV-positive support service programs where comprehensive post-infection healthcare
education is dispensed. As a result, we assume that a certain proportion of HIV-
positive individuals decide to reduce their risky sexual activities whilst the remaining
proportion does not. We thus assume a fraction ̺1 (respectively ̺2) of the w1Id(t)
individuals (respectively w2Idp(t)) tested HIV-positive and who have received the post-
infection education, are practising safe sex so that they are moved to the Ikn(t) class,
whilst the remaining (1 − ̺1)w1Id(t) individuals (respectively (1 − ̺2)w2Idp(t)) are
assumed to continue engaging in risky sexual activities, and thus move to the Ikr(t)
class. Infected individuals in the Ikn(t) class who have withdrawn from risky sexual
activities may relapse into risky behaviour at rate θw; and conversely, individuals in
Ikr(t) may change their sexual behaviour at a rate θa. The progression rates from
infected classes Id(t), Idp(t), Ikr(t), and Ikn(t) to the AIDS class A(t) are taken to be
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ρ1, ρ2, ρ3, and ρ4, respectively, so that ρ4 < ρ2 < ρ3 < ρ1. The natural death rate and
death related to the disease rate are assumed to be µ and δ, respectively. Individuals
are then recruited into the susceptible non-PrEP users class S(t), at a constant rate
π. A pictorial illustration of the flow of individuals in the seven classes is presented in
Figure 1 and mathematically modelled as follows:
Ṡ = π − γS − (1 − γ)λS + αSp − µS, (3)
Ṡp = γS − (1 − σ)λSp − (α + µ)Sp, (4)
İd = (1 − γ)λS − w1Id − (ρ1 + µ)Id, (5)
İdp = (1 − σ)λSp − w2Idp − (ρ2 + µ)Idp, (6)
İkr = (1 − ̺1)w1Id + (1 − ̺2)w2Idp + θwIkn − (θa + ρ3 + µ)Ikr, (7)
İkn = ̺1w1Id + ̺2w2Idp + θaIkr − (θw + ρ4 + µ)Ikn, (8)
Ȧ = ρ1Id + ρ2Idp + ρ3Ikr + ρ4Ikn − (µ+ δ)A, (9)
with non-negative initial conditions S(0) = S0, Sp(0) = Sp0, Id(0) = Id0, Idp(0) = Idp0,
Ikr(0) = Ikr0, Ikn(0) = Ikn0, and A(0) = A0. Here “ ˙ ” denotes the first derivative
with respect to time t.
3. Model analysis
3.1. Positivity and boundedness of the model solutions
It is easy to show that all solutions S(t), Sp(t), Id(t), Idp(t), Ikr(t), Ikn(t), and A(t) of
the system of equations (3)–(9), which basically represent human populations, starting
with non-negative initial values will remain non-negative for all the time. Moreover,
adding all the equations in (3)–(9) yields
Ṅ(t) = π − µN(t) − δA(t), (10)
which implies
Ṅ(t) + µN(t) ≤ π. (11)
Now, by applying a Theorem of Birkhoff and Rota [15] on differential inequalities, to
solve (11), we have







e−µt, t ≥ 0. (12)
Taking the limit as t → ∞ of equation (12) yields 0 ≤ N(t) ≤ π
µ
. This shows that
all solutions S(t), Sp(t), I(t), Idp(t), Ikr(t), Ikn(t), and A(t) of the system of equations
(3)–(9) are bounded on a maximal domain of existence given by
Ωm =
{





This shall therefore represent the admissible biological and feasible region of our model.
The region Ωm is a closed set where the model’s key features such as the existence, the
positivity, the uniqueness and the continuation of the solutions hold. One can show,
using results in [16], that the feasible region Ωm is positively invariant and attracting.

























Figure 1: The schematic diagram that depicts the HIV infection dynamics between the seven subclasses.
The dashed arrows depict the relapse on the preceding behaviour.
3.2. Equilibrium points of the model
The system (3)–(9) has two equilibrium points, the disease free equilibrium (DFE) point
given by
E0 = (S0, Sp0, Id0, Idp0, Ikr0, Ikn0, A0) =
(
π(α + µ)
µ(γ + α + µ)
,
γπ
µ(γ + α + µ)
, 0, 0, 0, 0, 0
)
, (13)
and the endemic equilibrium (EE) point given by
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Θ2 = (1 − σ)(1 − γ), Θ1 = (α + µ)(1 − γ) + (1 − σ)(γ + µ), Θ0 = µ(µ+ α + γ),
∆ri =
wi(θw + (1 − ̺i)(ρ4 + µ))
(ρ4 + µ)(ρ3 + µ+ θa) + θw(ρ3 + µ)
, ∆ni =
wi(θa + ̺i(ρ3 + µ))
(ρ4 + µ)(ρ3 + µ+ θa) + θw(ρ3 + µ)
.
Substituting equations (15)–(21) for the force of infection λ∗ in equation (2), we ob-
tained
P (λ∗) = λ∗(C2λ
∗2 + C1λ
∗ + C0) = 0, (22)
where
C0 = 1 − R0,
C1 =
1 − σ
γ + α + µ
+
α+ µ
γ + α + µ
(1 − γ)
ρ1 + w1 + µ
(












γ + α + µ
(1 − σ)
ρ2 + w2 + µ
(
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γ + α + µ
(1 − γ)
ρ1 + w1 + µ
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From (22), λ∗ = 0 corresponds to the DFE point and λ∗ = ((−C1+
√
C21 − 4C2C0)/2C2)
corresponds to endemic equilibrium, which exists only when λ∗ > 0, that is R0 > 1.
This result is summarized below.
Lemma 1. The endemic equilibrium point of the model exists only when R0 > 1.
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3.3. The control reproduction number R0
The average number of secondary infections that would produce a typical infected
individual in a purely susceptible population is known as the control reproduction
number, denoted by R0. This number is a very useful parameter in epidemic disease
models analyses as it represents the epidemic threshold. Thus, R0 is often used to
suggest conditions under which the epidemic’s outbreak will occur. The parameter R0
is mathematically defined as the spectral radius of the next generation matrix [17]. For
our system (3)–(9), the parameter R0 is given by
R0 = e∗γR1 + e∗σR2, (23)
where
e∗γ =
(1 − γ)(α + µ)
(γ + α + µ)
, e∗σ =
(1 − σ)γ




(ρ1 + µ+ w1)
+
cη3(θw + (1 − ̺1)(ρ4 + µ))w1




(ρ2 + µ+ w2)
+
cη3(θw + (1 − ̺2)(ρ4 + µ))w2
(ρ2 + µ+ w2)((ρ4 + µ)(ρ3 + µ+ θa) + θw(ρ3 + µ))
.
Examining each component of R0, it follows that
• R1 models the average number of new HIV infections generated by an infected
non-PrEP user individual who does not know his/her HIV status and an infected
non-PrEP user individual who now knows his/her HIV status but engaged in risky
sexual activities.
• R2 models the average number of new HIV infections generated by an infected
PrEP user individual who does not know that PrEP failed to protect him/her
and infected PrEP user individual, tested HIV-positive, and who still indulges in
risky sexual activities.
• The coefficient e∗γ , 0 < e∗γ < 1, measures the effectiveness of the PrEP awareness
whereas the coefficient e∗σ, 0 < e
∗
σ < 1, measures the effectiveness of PrEP ef-
ficacy level. In brief, the smaller the coefficients e∗γ and e
∗
σ are, the smaller the
contributions R1 and R2 have on R0.
3.4. Analysis of R0
We now carry on the model analysis investigating the impact of the variation of the
model parameter values on the control reproduction number R0. The analysis will help
in identifying the control parameters, whose an increase or decrease value would induce
the spread of the disease across the population. Analysis on the parameters are very
important in epidemic disease models as they can guide the design of a proper control
strategy.
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3.4.1. Effects of the control parameters on R0
We proceed by analysing the sensitivity of R0 with respect to the defined control pa-
rameters, γ, σ, ̺1, and ̺2.
We assess the impact of the PrEP awareness level on the new HIV infection rate by
computing
T γR0 = limγ→1 R0 = lime∗γ→0R0 =
1 − σ
1 + γ + µ
R2 < R0, (24)
which shows a reduction of the control reproduction number R0 to T γR0 , where T
γ
R0 < R0.
The result (24) shows that an increase in the proportion of the susceptible individuals on
PrEP use can be effective in controlling the spread of HIV infection in community, but
does not guarantee a total eradication of the disease. Efforts should be made to consider
PrEP drugs efficacy level as well. Note that when (γ, σ) tend to (1, 1) the disease is
completely eradicated (R0 tends to zero). In addition, remark that PrEP use awareness
has no impact on R0, when e∗γ = 1. This condition can not be attained since it implies
α + µ = −1, which is not possible. The contribution R1 into the infection progression
is therefore reduced by the coefficient e∗γ < 1. Note that when γ tends to unity (100%
effective), e∗γ tends to zero, that is, the more there are susceptible individuals on PrEP
use, the more the new HIV infection rate is reduced. The coefficient e∗γ thus measures
the effectiveness of the PrEP awareness.
Next we compute
T σR0 = limσ→1 R0 = lime∗σ→0R0 = e
∗
γR1 < R0, (25)
to investigate the impact of the PrEP drugs efficacy level on R0. We note from equa-
tion (25) that a significant increase in the efficacy of PrEP drugs would result in the
decline of new HIV infections (T σR0 < R0). We also note that the coefficient e∗σ < 1,
since e∗σ = 1 leads to σ = −α+µγ < 0, which is not possible. The contribution R2 on
R0 is therefore reduced by the coefficient e∗σ, so that 0 ≤ e∗σ < 1. As a result, one can
conclude that raising PrEP efficacy level will certainly reduce the HIV infection rate
but nevertheless does not guarantee a total elimination of the disease. The factor e∗σ
thus measures the effectiveness of the PrEP efficacy.
Finally, we investigate the benefits of post-infection educational services, which implic-
itly should highlight the benefits of more frequent and greater scope of HIV screening
programs. To do so, we compute
TR0 = lim
(̺1,̺2)→(1,1)
R0 = e∗γ lim
̺1→1
R1 + e∗σ lim
̺2→1
R2 = T ̺1R1 + T
̺2
R2 . (26)
Noting that T ̺1R1 < R1 and T
̺2
R2 < R2, it is clear that TR0 < R0. This suggests that
an increase in the proportion of infected individuals who withdraw from risky sexual
activities after being tested HIV positive would have a remarkable benefit in averting
new HIV infections. These call for regular HIV-test schedules followed by a strict post-
infection monitoring associated with elimination of HIV-related stigma, discrimination,
and regulation of punitive laws and practices.
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Table 1: The model parameter values (year−1) and their interpretations
Parameter Definition Value (range) Reference
γ PrEP awareness level 0.72 (0 − 0.99) [18]
σ PrEP efficacy level 0.92 (0.9 − 1.0) [19]
µ Natural death rate 0.025 (0.01− 0.025) [20]
δ Disease related deaths rate 0.33 (0.3 − 0.75) [21, 22]
θw Risky sexual withdrawal rate in
Ikn class
0.04 Assumed
π Recruitment rate 0.20 × 5 × 103 Assumed
α Non PrEP use relapse rate 0.015 Assumed
θa Risky sexual behaviour relapse
rate in Ikr class
0.01 Assumed
̺1, ̺2 Proportions of individuals who
abstain from risky sexual activ-
ities in Id and Idp class, respec-
tively
0.35, 0.65 Assumed
w1 HIV screening rate in Id class 0.30 [23]
w2 HIV screening rate in Idp class 0.45 Assumed
η1 HIV transmission rate per con-
tact with Id individual
1.215 Assumed
η2 HIV transmission rate per con-
tact with Idp individual
0.0219 [11]
η3 HIV transmission rate per con-
tact with Ikr individual
0.125 [20]
c Average number of risky sexual
acts
1.5 [24]
ρ1, ρ2, ρ3, ρ4 Progression rates to AIDS by Id,
Idp, Ikr and Ikn individuals, re-
spectively
0.074, 0.060, 0.068, 0.052 Assumed
3.4.2. Sensitivity analysis of the control parameters on R0
We carry on the analysis of the control reproduction number R0 with respect to the
control parameters γ, σ, ̺1, and ̺2 using the normalised forward sensitivity index
(n.f.s.i) theory [25]. Unlike the preceding analyses of R0, the n.f.s.i analysis helps one
to classify, in the most beneficial way to the least beneficial order, the control parameters
impact on the new infection rate reduction. This allows one to structure the control
strategies and interventions for successful HIV infection control.
Using the definition of the n.f.s.i in [25], the sensitivity index of R0 with respect to
the control parameters γ, σ, ̺1, and ̺2 are computed using the parameter values in
Table 1. We obtained the results as follows:
ΓR0̺1 = −0.057, ΓR0̺2 = −0.075, ΓR0γ = −1.335, ΓR0σ = −3.314. (27)
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Note that, ΓR0p > 0 indicates that increasing the value of parameter p would result
in an increase of the value of R0, whilst ΓR0p < 0 implies that increasing the value
of p would lead to a decrease in the value of R0. Thus, the results (27) reveal that
PrEP efficacy level σ is the most sensitive control parameter for the HIV infection
transmission control, followed by the proportion of susceptible individuals on PrEP use
γ, and then the proportions of the infected individuals who withdraw from risky sexual
behaviour ̺2, and ̺1.
4. Stability analysis of the model equilibrium points
The control reproduction number R0 is very crucial to the stability conditions of the
equilibrium points. We find the following:
Theorem 1. The disease free equilibrium point E0 of the model is globally asymptoti-
cally stable when R0 < 1 and unstable R0 > 1.
Theorem 2. The model endemic equilibrium point E∗ is globally asymptotically stable
when R0 > 1.
The proofs of these Theorems are standard, thus omitted.
5. Optimizing the control strategies
We now aim to investigate the optimal level of efforts and costs that would be needed to
control the HIV infection progress when PrEP intervention strategy and post-infection
service are implemented in a community.
We have seen from the above analysis of our model that HIV control intervention
strategies that account for higher level of the controls modelled would substantially
reduce the spread of HIV infection in communities and might lead to a total eradication
of the infection. However, raising the controls to higher levels, as it is required, will
be costly. Hence, a well-planned and efficient HIV control program implementation at
minimal cost is needed. Optimal control theory can help to obtain an appropriate plan
for a successful scheme.
To make use of the theory, we defined time dependent controls u1(t), u2(t), and u3(t), so
that 0 ≤ ui(t) ≤ 1, for i = 1, 2, 3. Note that when the controls are time dependent, the
disease free equilibrium no longer exists [26]. These controls are needed to model the
reinforcement of PrEP use campaigns and HIV educational campaigns policies as well
as PrEP drugs efficacy improvement. The time dependent controls u1(t) shall be tied
to new HIV infections reduction through expansion of PrEP intake campaigns during
which relevant knowledge and useful information about the benefits of using PrEP drugs
as efficacious prevention method will be provided. The control u2(t) should be tied to
the improvement of the efficacy level of the PrEP drugs provided. This would require
government financial support to make the drugs affordable. The control u3(t) shall
be tied to post-infection monitoring to ensure that the detected infected individuals
withdraw from risky sexual acts. This requires frequent HIV test campaigns. The
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Center for Disease Control and Prevention suggests that HIV testing in a PrEP program
be conducted every three months [27].
We thus modified our system (3)–(9) to the system of equations
Ṡ = π − u1S − (1 − u1)λS + αu2Sp − µS, (28)
Ṡp = u1S − (1 − u2)λSp − (αu2 + µ)Sp, (29)
İd = (1 − u1)λS − w1Id − (ρ1 + µ)Id, (30)
İdp = (1 − u2)λSp − w2Idp − (ρ2 + µ)Idp, (31)
İkr = (1 − ̺1u3)w1Id + (1 − ̺2u3)w2Idp + θwu3Ikn (32)
−(θa(1 − u3) + ρ3 + µ)Ikr, (33)
İkn = ̺1w1u3Id + ̺2w2u3Idp + θa(1 − u3)Ikr − (u3θw + ρ4 + µ)Ikn, (34)
Ȧ = ρ1Id + ρ2Idp + ρ3Ikr + ρ4Ikn − (µ+ δ)A, (35)
with the initial conditions S(0) = S0, Sp(0) = Sp0, Id(0) = Id0, Idp(0) = Idp0, Ikr(0) =
Ikr0, Ikn(0) = Ikn0, and A(0) = A0 .
We further formulate an objective functional J = J(u1, u2, u3) given by














subject to the state system (28)–(35), where tf is the final time of the control schedule
and the positive coefficients a1, a2, a3, b1, b2, and b3 are balancing cost factors that
transform the integral into money expended over a finite time. The objective functional
J(u1, u2, u3) is formulated such that the costs of infection a1Id, a2Idp, and a3Ikr are linear







and take quadratic forms. Note that this is consistent with other literature on optimal
control applied to epidemic disease models [28, 29].
Our endeavour involves minimizing the populations of infected individuals (Id,Idp, and







3) allocated onto each activity. In other words, we seek the optimal









3) = min {J(u1, u2, u3)|(u1, u2, u3) ∈ U} , (37)
where U =
{
u = (u1, u2, u3) ∈ L1[0, tf ], 0 ≤ ui ≤ 1, i = 1, 2, 3
}
, is the set of all possible
control triplets satisfying (36). Note that ui(t), 0 ≤ t ≤ tf , are bounded and Lebesgue
integrable.
The necessary conditions of existence of such triplets have been studied in [30] and
[31]. Using Pontryagin’s maximum principle [32], the optimality problem (system of
equations (28)–(37)) is converted into an equivalent problem, that is, a problem of
minimizing a pointwise Hamiltonian H, with respect to u1, u2, and u3, given by





where Gj(t) corresponds to the j
th state variable in the system (28)–(35), with the




= (λ1 − λ2) + λ(1 − u1)(λ1 − λ3) + λ1µ, (39)
dλ2
dt






(1 − u1)(λ1 − λ3) +
cη1Sp
N
(1 − u2)(λ2 − λ4) (41)






(1 − u1)(λ1 − λ3) +
cη2Sp
N
(1 − u2)(λ2 − λ4) (43)






(1 − u1)(λ1 − λ3) +
cη3Sp
N
(1 − u2)(λ2 − λ4) (45)
+ θa(1 − u3)(λ5 − λ6) + (λ5 − λ7)ρ3 + λ5µ, (46)
dλ6
dt
= θwu3(λ6 − λ5) + (λ6 − λ7)ρ4 + λ6µ, (47)
λ7
dt
= (µ+ δ)λ7, (48)
with the transversality conditions λj(tf) = 0, j = 1, . . . , 7.






, where Gj = [S, Sp, Id, Idp, Ikr, Ikn, A], j = 1, . . . , 7.
Using the existence results from Corollary 4.1 in [30], we state the following theorem




3) which minimizes the optimal func-
tional over the admissible set U is given by
u∗1 = min {1,max{0, û1}} , (49)
u∗2 = min {1,max{0, û2}} , (50)







































































∗ and λj, j = 1, . . . , 7 are solutions of (28)–(35) and (39)–
(48), respectively.
Proof. Results in equations (52)–(54) are obtained by differentiating the Hamiltonian










then solve for u1 = û1, u2 = û2, and u3 = û3. Next, taking into account the boundary
conditions defined in U , one can easily derive the result in (52)–(54).
Due to the priori boundedness of the states system (28)–(35) and the adjoints sys-
tem (39)–(48), and the resulting Lipschitz structure of the ODEs, the uniqueness of
the optimal control is obtained for the small time tf . The uniqueness of the optimal




3) follows from the uniqueness of the optimality system, which
consists of the fourteen ordinary differential equations (the states system and (28)–(35)
the corresponding adjoint system (39)–(48)) together with the control characteristics.
There is a restriction of the length of the time interval [0, tf ] in order to guarantee the
uniqueness of the optimality system. This smallest restriction of the length on the time
is due to the opposite time orientation of the adjoints system; the state system has
initial values and the corresponding adjoints system has final values.
6. Numerical results
We carried out the model analysis to numerically solve the optimality system. We
do this to explore and get better understanding of the potential effects of the optimal
control strategies on HIV burden. We used a forward-backward version of fourth or-
der Runge-Kutta scheme. The algorithm is described and presented in [33] as follows:
given initial values for the state variables S0, Sp0, Id0, Idp0, Ikr0, Ikn0, and A0 and initial




3, the states system (28)–(35)
is solved forward in time, and then using the resulting state values and the given final
time, the adjoint system (39)–(48) is then solved backward (and this because of the
traversality conditions). Furthermore, using both state and adjoints values obtained
from the iterations, the optimal triplet in (52)–(54) are updated. This process is re-
peated until the current states, adjoints, and the optimal control triplet values converge
sufficiently.
For a comprehensive and successful HIV PrEP implementation program, we suggest to
one to apply our modelled assumptions to a manageable size of populations (who are
at high risk of HIV infection); and this, simply for better follow-up and frequent HIV
screening to ensure that patients taking PrEP and who further have tested HIV-positive,
immediately stop PrEP intake and be offered post-infection counselling services. We
also suggest to consider population of individuals who are sufficiently mature to receive
PrEP adherence lessons (and who are sexually active). From report [21], individuals
aged between 15 and 49 years are more qualified. We thus defined an initial populations
size given as follows: S0 = 3600, Sp0 = 450, Id0 = 225, Idp0 = 50, Ikr0 = 60, Ikn0 = 0,
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and A0 = 0.
Report in 2012 on cost-effectiveness of PrEP use for HIV infection in South Africa
[34] estimated that HIV care with PrEP program cost to be US$9890 per years of life
save, compared to US$7280 cost for HIV care without PrEP. This gives b1 = 7280
and b2 = 9890. It is well known that pre-infection care is generally cheaper than post-
infection care. On that score, we assumed that the cost u3(t) allocated to post-infection
care is greater than the costs u1(t) and u2(t), which are cost tied to pre-infection cares.
We then assumed b3 = b1 + b2 = 17170. Intuitively, the corresponding efforts on each
duty are chosen to be a1 = 200, a2 = 400 and a3 = 600, respectively. The parameter
values used are obtained from the few available literature related to PrEP HIV pro-
gram. These values are summarized in Table 1. It is worth noting that the parsimonious
assumptions of the other parameters values fed from the scarcity and limited data on
PrEP use, at the moment. Nevertheless, we portray that these values are taken in the
realistic range for numerical simulations purpose.
The simulation results showing the time evolution of the infected populations Id(t),
Idp(t), and Ikr(t) and the susceptible non-PrEP users S(t) for situations where optimal
controls are considered (solid line) and where they are not (dashed line) are presented
in Figure 2; while those of the controls u1(t), u2(t), and u3(t) are shown in Figure 3.
From Figure 2(a), we observe a great decrease of the number of susceptible non-PrEP
users (at risk of becoming infected) at the initial times of PrEP program. However,
the results indicate that without optimal control the susceptible non-PrEP users would
resume to high risky behaviour after the first 5 years, whereas a significant risky be-
haviour reduction is marked when optimal control is considered. The profile of the
control tied to the increase of PrEP awareness scopes u1(t) is presented in Figure 3(a).
From the result, we observe that the control u1(t) monotonously remains at the up-
per bound till the final time. This suggests that PrEP awareness campaigns (during
which comprehensive PrEP use policies and PrEP use benefits knowledge are given by
recruited PrEP experts) are needed to be maintained highly consistent from the initial
time till the final time of the PrEP program.
In Figure 2(b)-(c), the time evolution of the infected non-PrEP users and infected PrEP
users are presented. In both figures, we observe a significant decrease of the number of
the infected individuals when optimal control is applied, from the initial implementa-
tion time of PrEP program, which progressively tends to zero (that is the infection free
point). On the other hand, we observe that without optimal control the number of in-
fected individuals in both classes (Id and Idp) steeply increases, reach its peak value and
then drops progressively to zero. These results clearly indicate that with application
of optimal control a much less time will be taken to eradicate the infection from the
population. With optimal control, we observe from Figure 2(b) that the infection free
point is reached within 30 years while from Figure 2(c), this is reached within 20 years.
The profile of the control tied to PrEP efficacy level improvement u2(t) is presented in
Figure 3(b). The control monotonously remains at the upper bound till the final time.
This reveals that PrEP efficacy is needed to be maintained at higher level from the
starting point of the PrEP program till the end in order to get an effective decline of
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Figure 2: Time evolution of the non-PrEP user S(t) and the infected Id(t), Idp(t) and Ikr(t) populations
over time with the given parameters and the initial state variables values.
new HIV infections cumulative in the population.
In Figure 2(d), we illustrate the time evolution of the population of the infected individ-
uals aware of their HIV status and who have not changed their risky sexual behaviour.
The results show a substantial reduction of the number of infected individuals indulged
in risky sexual behaviour when optimal control is applied compared to the case where
it is not. With optimal control, we observe that the peak value is reached within the
first 4 years while in the case without optimal control this is reached after 10 years.
Comparing the peaks values obtained in both cases, we have r ≈ 0.57, which infers
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Figure 3: Numerical results of the optimal controls u1(t), u2(t), and u3(t) over time.
57% risk reduction when optimal control is applied. The profile of the control tied to
the reinforcement of post-infection educational service u3(t), presented in Figure 3(c),
monotonously remains at the upper bound in the first 35 years and then hyperbolically
drops to zero. This suggests that the post-infection monitoring should be maintained
at the high level in the first 40 years.
7. Discussion and Conclusion
PrEP drugs use as HIV infection prevention intervention has been proven effective in
high risk infection settings (commercial sex workers, intravenous drugs users, homeless
people, or prison inmates). In this article, a homogeneous population at high risk of
HIV infection and where PrEP drugs are accessible is considered to analyse the impact
of PrEP drugs use and post-infection supports on HIV infection prevalence. A math-
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ematical model that subdivides the population with respect to their HIV status and
their health precaution care taken is developed and analysed. The infection threshold,
i.e the model control reproduction number (R0) is computed and qualitatively analysed
to gain insights into the infection dynamics. The proportion of the susceptible individ-
uals on PrEP use, the efficacy level of the drugs, and the proportion of the infected
individuals withdrawn from risky sexual contact are the key control factors targeted
for the model analysis. Sensitivity analysis of the variation of the control factors val-
ues on R0 was performed and the results suggest that new HIV infections reduction
would be significant when PrEP efficacy level is maintained at high level, followed by
the proportion of susceptible individuals on PrEP use and then the number of infected
individual withdrawn from risky sexual behaviour. Next, R0 is used to analyse the
stability conditions of the model equilibrium points. Results show that when R0 < 1,
the disease free equilibrium is stable and unstable otherwise; and when R0 > 1, the
endemic equilibrium point is globally asymptotically stable. Furthermore, optimal con-
trol theory using Pontryagin’s maximum principle is applied to our model introducing
time dependent control parameters for cost effective analysis. The optimality system
obtained is analysed and numerical simulations are performed. The results suggest that
new HIV infections reduction would be effective through PrEP intervention when time
dependent control is considered. These results indicate that with time dependent con-
trols (optimal controls) a much less time would be taken to reduce new HIV infections
in the population. The controls tied to the enlargement of PrEP use awareness scopes
and to the improvement of PrEP efficacy are to be maintained at the high level from
the initial time of the PrEP program until the end if the PrEP intervention is to be ef-
fective. For the control tied to the post-infection policies reinforcement, the simulations
suggest that effective and prompt post-infection education services should be provided
to ensure maximum change of risk behavioural in the first 35 years.
We suggest more HIV healthcare experts recruitment for sufficient and effective post-
infection monitoring, intensive comprehensive PrEP drugs intake policies communica-
tion, zero tolerance of application of HIV-positive individuals stigmatization and dis-
crimination punitive laws, face-to-face consultation for individuals with low literacy to
build an ongoing dialogue regarding the benefit of risky behavioural reduction, and con-
sistent reminder of additional preventive methods (such as condoms use, faithfulness,
less sexually active partners acquisition) to the PrEP drugs intake or consistence and
timely use of PrEP drugs.
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This research study is focused on developing and analysing mathematical HIV models, which
comprise systems of ordinary differential equations that capture the dynamics of HIV infection
under PrEP intervention and PrEP in combination with other HIV control approaches. The
analysis and the results obtained from these models are to contribute to the ongoing investiga-
tions and understanding of the potential ability of PrEP use by HIV-uninfected individual to
reduce the likelihood of sexual HIV infection acquisition and outline the benefits of combining
PrEP with HIV infection control intervention such as early ART and risk reduction educational
in post-HIV infection intervention.
Underlying development surrounding the origin and progression of HIV/AIDS disease were
presented. Recent advances in HIV infection prevention and treatment approaches were also
reviewed as well as the current HIV prevention strategies (use of ARV for PrEP). Our study
tapped into the current prevention intervention strategies and putting into context the benefits
of combining these and other already existing strategies.
In chapter 2, we formulated a mathematical PrEP model by extending the standard SIR model
incorporating two key PrEP control factors, that is, PrEP efficacy and PrEP use awareness for
analysis. The model analysis was carried out and conditions under which the endemicity level of
HIV infection can be brought under control (R0 < 1) with PrEP intervention were established.
Four hypothetical PrEP strategies, characterizing the quality of both PrEP factors (low/high
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PrEP use awareness and low/high PrEP efficacy) were thus considered. The results show that
in most of these strategies considered, the model epidemic threshold R0 stayed above unity
except for the strategy where high PrEP awareness (> 85%) and high PrEP efficacy (> 85%)
is implemented. This implies that the strategy of high PrEP awareness and high PrEP effi-
cacy significantly reduces HIV incidence better than any other strategy. Moreover, we note
that even at high levels of awareness, R0 remains close to unity, which indicates that PrEP
intervention alone as a mono-strategy may not continuously keep the HIV burden under check.
This observation reveals the necessity of associating PrEP implementation with other forms of
intervention such as effective use of male and female condoms, ARV treatment intervention and
home-based care. The study in [68] reported that PrEP efficacy of at least 80 percent was able
to reduce the basic reproduction ratio below unity. Our results in this study with parameter
values from the South African HIV statistics [74] are in agreement with those results.
Note, however, that maintaining PrEP awareness and PrEP efficacy at such high levels in the
long-term would pose a big challenge, since it would demand considerable effort and funds as
well as sufficient recruitment and effective training of PrEP drugs’ providers for proper mon-
itoring and follow up of PrEP users, plus the subsidization of the price of high efficacy PrEP
drugs. On the other hand, this would require a strict adherence of individuals to the PrEP
drug uptake and effective monitoring efforts for appropriate follow up of PrEP users.
In chapter 3, we modified the PrEP model incorporating ARV use for treatment to assess
the impact of combining PrEP intervention as a pre-infection control and ARV use as a post-
infection control in the fight against new HIV infections. We also considered drug resistance,
which is one of the crucial factors that potentially impedes the overall effectiveness of PrEP
intervention. PrEP drug resistance often emerges from PrEP used by pre-infected individu-
als. Thus, a new class of infected individuals was incorporated into the modified model. The
model analysis showed that HIV incidence would be more significantly reduced when PrEP and
ARVs interventions are concurrently implemented at high rates, compared to PrEP or ARV
intervention as a single control strategy. Similar observations were also reported from other
studies [59, 92, 129]. A mathematical model was developed and analysed in [93] to access the
impact of the current ARV use as a pre-exposure vaccine in controlling HIV infection. Their
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results also recommended a combination of PrEP and ART interventions in the fight to new
HIV infections. However, the authors did not consider PrEP drug resistance, which is one of
the most important factors that usually impede PrEP efficacy. Our model results also reveal
that the increase in the number of misdiagnosed infected individuals on PrEP use could be a
key driver of the HIV infection spread. Moreover, the results exhibited that the contribution
of PrEP drug resistance to the spread of HIV infection would partially depend on the duration
of PrEP use by the already-infected individuals. This demands regular HIV screening (at least
every 3 months as recommended by CDC), as well as proper monitoring and follow-up during
the pre- and post-randomized PrEP prescription protocols.
In Chapter 4, post-infection educational support service (for risk behaviour change in the de-
tected infected individuals) is introduced into the PrEP model. Discontinuity of PrEP intake
was incorporated. In the first part, investigation of the steady-state conditions of the model
equilibrium points were carried out while in the second part, optimal control theory using
Pontryagins Maximum Principle was applied to the model. Time dependent control variables
(policies) for cost effective analysis were thus formulated. The results highlighted that a combi-
nation of PrEP intervention and post-HIV infection educational support service is very effective
in minimizing the population of infected individuals indulging in risky sexual behaviour and
hence resulting in a great decline in HIV incidence and prevalence. The results also demon-
strated that with optimal controls, new HIV infections will be eradicated in a much shorter time
and with cost saving benefits, compared to the case without optimal controls. The simulations
show that the control policies must be maintained constantly at high levels with maximum
efforts deployed in post-HIV infection support from the initial time until the end.
In summmary our study in this thesis seems to suggest that
• PrEP intervention with low PrEP awareness and low PrEP drugs efficacy may to some
extend reduce the endemicity level of HIV infection but would remain an ineffective
approach to reach the total eradication target.
• High PrEP awareness that optimizes adherence among PrEP users and high PrEP efficacy
are urgently needed if the cumulative number of new HIV infections is to be reduced.
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• PrEP intervention alone (even at high levels) cannot mitigate the HIV infection burden
in the long-term just like other pre-existing intervention strategies. The PrEP control
may be much more beneficial if used in combination with other effective HIV control
strategies.
• PrEP for prevention and ART for treatment (when both are concurrently implemented)
would significantly reduce HIV incidence and might possibly led to zero new HIV infec-
tions.
• Combination of PrEP intervention with risk behaviour reduction education (which seeks
to minimize the population of infected individuals indulging in risky sexual behaviour)
would have a great impact in declining HIV incidence and prevalence. The decline is
achievable in a much shorter time and with cost saving benefits when optimal controls
are considered, compared to the case without optimal controls.
Our findings in this project have great implications for ongoing investigations and planning of
HIV control and effective PrEP and PrEP in combination with other pre-existing prevention
approaches implementation for HIV infection control. In addition to these findings, we recom-
mend that if HIV infection is to be eradicated through effective PrEP intervention and PrEP
associated with other strategies, intensive PrEP use awareness through media and other means
of communication, introduction of PrEP use knowledge and distribution of PrEP guideline
books in high learning institutions as well as public and recreation places must take place for
maximum awareness of PrEP protection benefits among young adults. Before an individual
begins PrEP, we recommend an initial 30 day follow up visit to assess the eligibility, commit-
ment, safety, and effective use of PrEP drugs, then a prescription for 60 days, after which,
sexual transmission infection screening and HIV test should be performed. This could help to
reduce the occurrence of drug resistance. We also recommend a large number of HIV healthcare
expert recruitment for sufficient and effective monitoring and a monthly home-based discus-
sion and follow up for individuals with low literacy. In addition, there should be a consistent
reminder of additional preventive methods (such as condoms use, faithfulness, less sexually
active partners acquisition) to the PrEP drugs intake or consistence and timely use of PrEP
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drugs. We also recommend establishment of regulations against illegal and unlicensed PrEP
drugs distribution to avoid provision of fake PrEP drugs. We suggest the solicitation of medical
insurance organisations and governmental health stakeholder involvement for financial support
to ensure that the price of high efficacy PrEP drugs is subsidized. We also suggest provision of
tools and devices for reminders and timely intake of PrEP drugs. Early enrolment into ART of
individuals whom PrEP failed to protect and those who are diagnosed pre-infected before PrEP
is crucial. We recommend promotion of community empowerment, peer education, promotion
of minimum sexual partners, identification of hidden sexual workers settings, enlargement of
HIV voluntary counselling and testing scopes, distribution of HIV heath educational materials
and guidelines.
We acknowledge that the models developed and analysed in this thesis could not capture all
the important social factors intervening in HIV infection dynamics under control of PrEP and
PrEP in combination with ART interventions and risk reduction educational services. Thus,
our findings cannot be regarded as a perfect prediction for PrEP use but rather a guideline for
an effective PrEP implementation plan for optimum protection benefit and cost effectiveness.
Our models therefore offer an opportunity for modifications which can be achieved by refining
the epidemiological assumptions and formulating better assumptions that would improve the
model outcomes. The following aspect are some of the important factors that can be considered
in improving the predictions in our study.
• Adherence to PrEP drugs varies from one user to another. Incorporation of stochasticity
in the models in dealing with variability inherent in any dynamical process is an important
aspect to be considered.
• Individuals of different ages may respond differently to PrEP use and reduction of risk
behaviour might vary among age groups. Young individuals in the age range [15-30] years
are more active in interactions with or between populations than individuals aged between
[30-49]. The model would give more insights if an age-structure property is introduced.
• Data on PrEP and ART for improvement and validation of the models outcomes are
important steps to be considered. Data fitting provides appropriate values of our model
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parameters. Our study did not present any data fitting due to scarcity of data in current
PrEP trials.
• Evidence demonstrated that the level of protection of both PrEP drugs (Tenofovir and
Truvada) depends on the dose absorbed in the body. Truvada is proven to be more rapidly
absorbed than Tenofovir. Tenofovir takes 24 hours while Truvada takes 30 minutes to be
absorbed in both vaginal and rectal tissue. Time delay is therefore an important factor
to be taken into account. Thus, time dependent delay aspects can be incorporated into
our deterministic models for more realistic outcomes.
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